-- challenge_platform data

INSERT INTO challenge_platform (id, slug, name, avatar_url, website_url)
VALUES (
    '1',
    'synapse',
    'Synapse',
    'https://via.placeholder.com/300.png',
    'https://synapse.org/'
  ),
  (
    '2',
    'cagi',
    'CAGI',
    'https://via.placeholder.com/300.png',
    'https://genomeinterpretation.org/challenges.html'
  ),
  (
    '3',
    'cami',
    'CAMI',
    'https://via.placeholder.com/300.png',
    'https://data.cami-challenge.org/'
  ),
  (
    '4',
    'casp',
    'CASP',
    'https://via.placeholder.com/300.png',
    'https://predictioncenter.org/'
  ),
  (
    '5',
    'grand-challenge',
    'Grand Challenge',
    'https://via.placeholder.com/300.png',
    'https://grand-challenge.org/'
  ),
  (
    '6',
    'precision-fda',
    'precisionFDA',
    'https://via.placeholder.com/300.png',
    'https://precision.fda.gov/challenges'
  ),
  (
    '7',
    'easychair',
    'EasyChair',
    'https://via.placeholder.com/300.png',
    'https://easychair.org/'
  ),
  (
    '8',
    'kaggle',
    'Kaggle',
    'https://via.placeholder.com/300.png',
    'https://www.kaggle.com/'
  ),
  (
    '9',
    'codalab',
    'CodaLab',
    'https://via.placeholder.com/300.png',
    'https://codalab.lisn.upsaclay.fr/'
  ),
  (
    '10',
    'codabench',
    'CodaBench',
    'https://via.placeholder.com/300.png',
    'https://www.codabench.org/'
  ),
  (
    '11',
    'openml',
    'OpenML',
    'https://via.placeholder.com/300.png',
    'https://www.openml.org/'
  ),
  (
    '12',
    'papers-with-code',
    'PapersWithCode',
    'https://via.placeholder.com/300.png',
    'https://paperswithcode.com/'
  );

-- challenge_input_data_type

INSERT INTO challenge_input_data_type (id, slug, name)
VALUES ('1', 'genomic', 'genomic'),
  ('2', 'proteomic', 'proteomic'),
  ('3', 'gene-expression', 'gene expression'),
  ('4', 'metabolomic', 'metabolomic');

-- challenge data

INSERT INTO challenge (
    id,
    slug,
    name,
    headline,
    description,
    website_url,
    status,
    difficulty,
    platform_id,
    start_date,
    end_date
  )
VALUES (
    '1',
    'network-topology-and-parameter-inference',
    'Network Topology and Parameter Inference',
    '',
    'Participants are asked to develop and/or apply optimization methods, including the selection of the most informative experiments, to accurately estimate parameters and
 predict outcomes of perturbations in Systems Biology models.',
    'https://www.synapse.org/#!Synapse:syn2821735',
    'completed',
    'intermediate',
    '1',
    '2012-06-01',
    '2012-10-01'
  ),
  (
    '2',
    'breast-cancer-prognosis',
    'Breast Cancer Prognosis',
    '',
    'The goal of the breast cancer prognosis Challenge is to assess the accuracy of computational models designed to predict breast cancer survival, based on clinical information about the patient''s tumor as well as genome-wide molecular profiling data including gene expression ...',
    'https://www.synapse.org/#!Synapse:syn2813426',
    'completed',
    'intermediate',
    '1',
    '2012-07-12',
    '2012-10-15'
  ),
  (
    '3',
    'phil-bowen-als-prediction-prize4life',
    'Phil Bowen ALS Prediction Prize4Life',
    '',
    'Amyotrophic Lateral Sclerosis (ALS)–also known as Lou Gehrig’s disease (in the US) or Motor Neurone disease (outside the US)–is a fatal neurological disease causing death of the nerve cells in the brain and spinal cord which control voluntary muscle movements. This leaves pa...',
    'https://www.synapse.org/#!Synapse:syn2826267',
    'completed',
    'intermediate',
    '1',
    '2012-06-01',
    '2012-10-01'
  ),
  (
    '4',
    'drug-sensitivity-and-drug-synergy-prediction',
    'Drug Sensitivity and Drug Synergy Prediction',
    '',
    'Development of new cancer therapeutics currently requires a long and protracted process of experimentation and testing. Human cancer cell lines represent a good model to help identify associations between molecular subtypes, pathways, and drug response. In recent years there...',
    'https://www.synapse.org/#!Synapse:syn2785778',
    'completed',
    'intermediate',
    '1',
    '2012-06-01',
    '2012-10-01'
  ),
  (
    '5',
    'niehs-ncats-unc-toxicogenetics',
    'NIEHS-NCATS-UNC Toxicogenetics',
    '',
    'This challenge is designed to build predictive models of cytotoxicity as mediated by exposure to environmental toxicants and drugs. To approach this question, we will provide a dataset containing cytotoxicity estimates as measured in lymphoblastoid cell lines derived from 88...',
    'https://www.synapse.org/#!Synapse:syn1761567',
    'completed',
    'intermediate',
    '1',
    '2013-06-10',
    '2013-09-15'
  ),
  (
    '6',
    'whole-cell-parameter-estimation',
    'Whole-Cell Parameter Estimation',
    '',
    'The goal of this challenge is to explore and compare innovative approaches to parameter estimation of large, heterogeneous computational models. Participants are encouraged to develop and/or apply optimization methods, including the selection of the most informative experime...',
    'https://www.synapse.org/#!Synapse:syn1876068',
    'completed',
    'intermediate',
    '1',
    '2013-06-10',
    '2013-09-23'
  ),
  (
    '7',
    'hpn-dream-breast-cancer-network-inference',
    'HPN-DREAM Breast Cancer Network Inference',
    '',
    'The overall goal of the Heritage-DREAM breast cancer network inference challenge is to quickly and effectively advance our ability to infer causal signaling networks and predict protein phosphorylation dynamics in cancer. We provide extensive training data from experiments o...',
    'https://www.synapse.org/#!Synapse:syn1720047',
    'completed',
    'intermediate',
    '1',
    '2013-06-10',
    '2013-09-16'
  ),
  (
    '8',
    'rheumatoid-arthritis-responder',
    'Rheumatoid Arthritis Responder',
    '',
    'The goal of this project is to use a crowd-based competition framework to develop a validated molecular predictor of anti-TNF response in RA. There is an increasing need for predictors of response to therapy in inflammatory disease driven by the observation that most clinica...',
    'https://www.synapse.org/#!Synapse:syn1734172',
    'completed',
    'intermediate',
    '1',
    '2014-02-10',
    '2014-06-04'
  ),
  (
    '9',
    'smc-dna',
    'SMC-DNA',
    '',
    'The ICGC-TCGA DREAM Genomic Mutation Calling Challenge (herein, The Challenge) is an international effort to improve standard methods for identifying cancer-associated mutations and rearrangements in whole-genome sequencing (WGS) data. Leaders of the International Cancer Gen...',
    'https://www.synapse.org/#!Synapse:syn312572',
    'completed',
    'intermediate',
    '1',
    '2013-12-14',
    '2016-04-22'
  ),
  (
    '10',
    'acute-myeloid-leukemia-outcome-prediction',
    'Acute Myeloid Leukemia Outcome Prediction',
    '',
    'The AML Outcome Prediction Challenge provides a unique opportunity to access and interpret a rich dataset for AML patients that includes clinical covariates, select gene mutation status and proteomic data. Capitalizing on a unique AML reverse phase protein array (RPPA) datas...',
    'https://www.synapse.org/#!Synapse:syn2455683',
    'completed',
    'intermediate',
    '1',
    '2014-06-02',
    '2014-09-15'
  ),
  (
    '11',
    'broad-dream-gene-essentiality-prediction',
    'Broad-DREAM Gene Essentiality Prediction',
    '',
    'The goal of this project is to use a crowd-based competition to develop predictive models that can infer gene dependency scores in cancer cells (genes that are essential to cancer cell viability when suppressed) using features of those cell lines. An additional goal is to fi...',
    'https://www.synapse.org/#!Synapse:syn2384331',
    'completed',
    'intermediate',
    '1',
    '2014-06-02',
    '2014-09-29'
  ),
  (
    '12',
    'alzheimers-disease-big-data',
    'Alzheimer''s Disease Big Data',
    '',
    'The goal of the Alzheimer''s Disease Big Data DREAM Challenge #1 (AD#1) was to apply an open science approach to rapidly identify accurate predictive AD biomarkers that can be used by the scientific, industrial and regulatory communities to improve AD diagnosis and treatment...',
    'https://www.synapse.org/#!Synapse:syn2290704',
    'completed',
    'intermediate',
    '1',
    '2014-06-02',
    '2014-10-17'
  ),
  (
    '13',
    'olfaction-prediction',
    'Olfaction Prediction',
    '',
    'The goal of the DREAM Olfaction Prediction Challenge is to find models that can predict how a molecule smells from its physical and chemical features. A model that allows us to predict a smell from a molecule will provide fundamental insights into how odor chemicals are tran...',
    'https://www.synapse.org/#!Synapse:syn2811262',
    'completed',
    'intermediate',
    '1',
    '2015-01-15',
    '2015-05-01'
  ),
  (
    '14',
    'prostate-cancer',
    'Prostate Cancer',
    '',
    'This challenge will attempt to improve the prediction of survival and toxicity of docetaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognost...',
    'https://www.synapse.org/#!Synapse:syn2813558',
    'completed',
    'intermediate',
    '1',
    '2015-03-16',
    '2015-07-27'
  ),
  (
    '15',
    'als-stratification-prize4life',
    'ALS Stratification Prize4Life',
    '',
    'As illustrated by the overview figure below, (a) Challenge Data includes data from ALS clinical trials and ALS registries. ALS clinical trials consist of patients from clinical trials available open access on the PRO-ACT database and patients from 6 clinical trials not yet a...',
    'https://www.synapse.org/#!Synapse:syn2873386',
    'completed',
    'intermediate',
    '1',
    '2015-06-22',
    '2015-10-04'
  ),
  (
    '16',
    'astrazeneca-sanger-drug-combination-prediction',
    'AstraZeneca-Sanger Drug Combination Prediction',
    '',
    'To accelerate the understanding of drug synergy, AstraZeneca has partnered with the European Bioinformatic Institute, the Sanger Institute, Sage Bionetworks, and the distributed DREAM community to launch the AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge. Thi...',
    'https://www.synapse.org/#!Synapse:syn4231880',
    'completed',
    'intermediate',
    '1',
    '2015-09-03',
    '2016-03-14'
  ),
  (
    '17',
    'smc-dna-meta',
    'SMC-DNA Meta',
    '',
    'The goal of this Challenge is to identify the most accurate meta-pipeline for somatic mutation detection, and establish the state-of-the-art. The algorithms in this Challenge must use as input mutations predicted by one or more variant callers and output mutation calls assoc...',
    'https://www.synapse.org/#!Synapse:syn4588939',
    'completed',
    'intermediate',
    '1',
    '2015-08-17',
    '2016-04-10'
  ),
  (
    '18',
    'smc-het',
    'SMC-Het',
    '',
    'The ICGC-TCGA DREAM Somatic Mutation Calling - Tumour Heterogeneity Challenge (SMC-Het) is an international effort to improve standard methods for subclonal reconstruction: to quantify and genotype each individual cell population present within a tumor. Leaders of the Intern...',
    'https://www.synapse.org/#!Synapse:syn2813581',
    'completed',
    'intermediate',
    '1',
    '2015-11-16',
    '2016-06-30'
  ),
  (
    '19',
    'respiratory-viral',
    'Respiratory Viral',
    '',
    'Respiratory viruses are highly infectious and cause acute illness in millions of people every year. However, there is wide variation in the physiologic response to exposure at the individual level. Some people that are exposed to virus are able to completely avoid infection....',
    'https://www.synapse.org/#!Synapse:syn5647810',
    'completed',
    'intermediate',
    '1',
    '2016-05-16',
    '2016-09-28'
  ),
  (
    '20',
    'disease-module-identification',
    'Disease Module Identification',
    '',
    'The Disease Module Identification DREAM Challenge is an open community effort to systematically assess module identification methods on a panel of state-of-the-art genomic networks and leverage the “wisdom of crowds” to discover novel modules and pathways underlying complex ...',
    'https://www.synapse.org/#!Synapse:syn6156761',
    'completed',
    'intermediate',
    '1',
    '2016-06-24',
    '2016-10-01'
  ),
  (
    '21',
    'encode',
    'ENCODE',
    '',
    'Transcription factors (TFs) are regulatory proteins that bind specific DNA sequence patterns (motifs) in the genome and affect transcription rates of target genes. Binding sites of TFs differ across cell types and experimental conditions. Chromatin immunoprecipitation follow...',
    'https://www.synapse.org/#!Synapse:syn6131484',
    'completed',
    'intermediate',
    '1',
    '2016-07-07',
    '2017-01-11'
  ),
  (
    '22',
    'idea',
    'Idea',
    '',
    'The DREAM Idea Challenge is designed to collaboratively shape and enable the solution of a question fundamental to improving human health. In the process, all proposals and their evaluation will be made publicly available for the explicit purpose of connecting modelers and e...',
    'https://www.synapse.org/#!Synapse:syn5659209',
    'completed',
    'advanced',
    '1',
    '2016-06-15',
    '2017-04-30'
  ),
  (
    '23',
    'smc-rna',
    'SMC-RNA',
    '',
    'The ICGC-TCGA DREAM Somatic Mutation Calling - RNA Challenge (SMC-RNA) is an international effort to improve standard methods for identifying cancer-associated rearrangements in RNA sequencing (RNA-seq) data. Leaders of the International Cancer Genome Consortium (ICGC) and T...',
    'https://www.synapse.org/#!Synapse:syn2813589',
    'completed',
    'intermediate',
    '1',
    '2016-06-29',
    '2017-05-02'
  ),
  (
    '24',
    'digital-mammography',
    'Digital Mammography',
    '',
    'The Digital Mammography DREAM Challenge will attempt to improve the predictive accuracy of digital mammography for the early detection of breast cancer. The primary benefit of this Challenge will be to establish new quantitative tools - machine learning, deep learning or oth...',
    'https://www.synapse.org/#!Synapse:syn4224222',
    'completed',
    'advanced',
    '1',
    '2016-11-18',
    '2017-05-16'
  ),
  (
    '25',
    'multiple-myeloma',
    'Multiple Myeloma',
    '',
    'Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, with about 25,000 newly diagnosed patients per year in the United States alone. The disease''s clinical course depends on a complex interplay of clinical traits and molecular characteristics of the pla...',
    'https://www.synapse.org/#!Synapse:syn6187098',
    'completed',
    'intermediate',
    '1',
    '2017-06-30',
    '2017-11-08'
  ),
  (
    '26',
    'ga4gh-dream-workflow-execution',
    'GA4GH-DREAM Workflow Execution',
    '',
    'The highly distributed and disparate nature of genomic and clinical data generated around the world presents an enormous challenge for those scientists who wish to integrate and analyze these data. The sheer volume of data often exceeds the capacity for storage at any one si...',
    'https://www.synapse.org/#!Synapse:syn8507133',
    'completed',
    'intermediate',
    '1',
    '2017-07-21',
    '2017-12-31'
  ),
  (
    '27',
    'parkinsons-disease-digital-biomarker',
    'Parkinson''s Disease Digital Biomarker',
    '',
    'The Parkinson''s Disease Digital Biomarker DREAM Challenge is a first of it''s kind challenge, designed to benchmark methods for the processing of sensor data for development of digital signatures reflective of Parkinson''s Disease. Participants will be provided with raw sens...',
    'https://www.synapse.org/#!Synapse:syn8717496',
    'completed',
    'intermediate',
    '1',
    '2017-07-06',
    '2017-11-10'
  ),
  (
    '28',
    'nci-cptac-proteogenomics',
    'NCI-CPTAC Proteogenomics',
    '',
    'Cancer is driven by aberrations in the genome [1,2], and these alterations manifest themselves largely in the changes in the structure and abundance of proteins, the main functional gene products. Hence, characterization and analyses of alterations in the proteome has the pr...',
    'https://www.synapse.org/#!Synapse:syn8228304',
    'completed',
    'intermediate',
    '1',
    '2017-06-26',
    '2017-11-20'
  ),
  (
    '29',
    'multi-targeting-drug',
    'Multi-Targeting Drug',
    '',
    'The objective of this challenge is to incentivize development of methods for predicting compounds that bind to multiple targets. In particular, methods that are generalizable to multiple prediction problems are sought. To achieve this, participants will be asked to predict 2...',
    'https://www.synapse.org/#!Synapse:syn8404040',
    'completed',
    'intermediate',
    '1',
    '2017-10-05',
    '2018-02-26'
  ),
  (
    '30',
    'single-cell-transcriptomics',
    'Single Cell Transcriptomics',
    '',
    'In this Challenge on Single-Cell Transcriptomics, participants will reconstruct the location of single cells in the Drosophila embryo using single-cell transcriptomic data. Data will be made available in late August and participating challenge teams can work on the data and ...',
    'https://www.synapse.org/#!Synapse:syn15665609',
    'completed',
    'intermediate',
    '1',
    '2018-09-04',
    '2018-11-21'
  ),
  (
    '31',
    'idg-drug-kinase-binding',
    'IDG Drug-Kinase Binding',
    '',
    'This IDG-DREAM Drug-Kinase Binding Prediction Challenge seeks to evaluate the power of statistical and machine learning models as a systematic and cost-effective means for catalyzing compound-target interaction mapping efforts by prioritizing most potent interactions for fur...',
    'https://www.synapse.org/#!Synapse:syn15667962',
    'completed',
    'intermediate',
    '1',
    '2018-10-01',
    '2019-04-18'
  ),
  (
    '32',
    'malaria',
    'Malaria',
    '',
    'The Malaria DREAM Challenge is open to anyone interested in contributing to the development of computational models that address important problems in advancing the fight against malaria. The overall goal of the first Malaria DREAM Challenge is to predict Artemisinin (Art) d...',
    'https://www.synapse.org/#!Synapse:syn16924919',
    'completed',
    'intermediate',
    '1',
    '2019-04-30',
    '2019-08-15'
  ),
  (
    '33',
    'preterm-birth-prediction-transcriptomics',
    'Preterm Birth Prediction - Transcriptomics',
    '',
    'A basic need in pregnancy care is to establish gestational age, and inaccurate estimates may lead to unnecessary interventions and sub-optimal patient management. Current approaches to establish gestational age rely on patient’s recollection of her last menstrual period and/...',
    'https://www.synapse.org/#!Synapse:syn18380862',
    'completed',
    'good_for_beginners',
    '1',
    '2019-05-04',
    '2019-12-05'
  ),
  (
    '34',
    'single-cell-signaling-in-breast-cancer',
    'Single-Cell Signaling in Breast Cancer',
    '',
    'Signaling underlines nearly every cellular event. Individual cells, even if genetically identical, respond to perturbation in different ways. This underscores the relevance of cellular heterogeneity, in particular in how cells respond to drugs. This is of high relevance sinc...',
    'https://www.synapse.org/#!Synapse:syn20366914',
    'completed',
    'intermediate',
    '1',
    '2018-08-20',
    '2019-11-15'
  ),
  (
    '35',
    'ehr-mortality-prediction',
    'EHR Mortality Prediction',
    '',
    'The recent advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA mutations induced by CRISPR during development and promises to solve the lineage of complex model organisms at single-cell resolution ...',
    'https://www.synapse.org/#!Synapse:syn18405991',
    'completed',
    'intermediate',
    '1',
    '2019-09-09',
    '2020-01-23'
  ),
  (
    '36',
    'allen-institute-cell-lineage-reconstruction',
    'Allen Institute Cell Lineage Reconstruction',
    '',
    'The recent advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA mutations induced by CRISPR during development and promises to solve the lineage of complex model organisms at single-cell resolution....',
    'https://www.synapse.org/#!Synapse:syn20692755',
    'completed',
    'intermediate',
    '1',
    '2019-10-15',
    '2020-02-06'
  ),
  (
    '37',
    'tumor-deconvolution',
    'Tumor Deconvolution',
    '',
    'The extent of stromal and immune cell infiltration within solid tumors has prognostic and predictive significance. Unfortunately, expression profiling of tumors has, until very recently, largely been undertaken using bulk techniques (e.g., microarray and RNA-seq). Unlike sin...',
    'https://www.synapse.org/#!Synapse:syn15589870',
    'completed',
    'intermediate',
    '1',
    '2019-06-26',
    '2020-04-30'
  ),
  (
    '38',
    'ctd2-pancancer-drug-activity',
    'CTD2 Pancancer Drug Activity',
    '',
    'NCI Genomic Data Commons,Harvard Chan School, Blue Collar Bioinformatics,ENCODE DCC, Stanford,CCHMC, Barski Lab,KnowEnG, UIUC,UCSC,OICR, ICGC,Broad Institute, GATK',
    'https://www.synapse.org/#!Synapse:syn20968331',
    'completed',
    'good_for_beginners',
    '1',
    '2019-12-02',
    '2020-02-13'
  ),
  (
    '39',
    'ctd2-beataml',
    'CTD2 BeatAML',
    '',
    'In the era of precision medicine, AML patients have few therapeutic options, with “7 + 3” induction chemotherapy having been the standard for decades (Bertoli et al. 2017). While several agents targeting the myeloid marker CD33 or alterations in FLT3 or IDH2 have demonstrate...',
    'https://www.synapse.org/#!Synapse:syn20940518',
    'completed',
    'good_for_beginners',
    '1',
    '2019-12-19',
    '2020-04-28'
  ),
  (
    '40',
    'metadata-automation',
    'Metadata Automation',
    '',
    'The Cancer Research Data Commons (CRDC) will collate data across diverse groups of cancer researchers, each collecting biomedical data in different formats. This means the data must be retrospectively harmonized and transformed to enable this data to be submitted. In additio...',
    'https://www.synapse.org/#!Synapse:syn18065891',
    'completed',
    'intermediate',
    '1',
    '2020-01-14',
    '2020-06-02'
  ),
  (
    '41',
    'automated-scoring-of-radiographic-joint-damage',
    'Automated Scoring of Radiographic Joint Damage',
    '',
    'The purpose of the RA2-DREAM Challenge is to develop an automated method to quickly and accurately quantify the degree of joint damage associated with rheumatoid arthritis (RA). Based on radiographs of the hands and feet, a novel, automated scoring method could be applied br...',
    'https://www.synapse.org/#!Synapse:syn20545111',
    'completed',
    'intermediate',
    '1',
    '2019-11-04',
    '2020-05-21'
  ),
  (
    '42',
    'beat-pd',
    'BEAT-PD',
    '',
    'Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for quantitative, remote monitoring of health and disease - particularly for diseases affecting motor function such as Parkinson’s disease. Such approaches have been roll...',
    'https://www.synapse.org/#!Synapse:syn20825169',
    'completed',
    'intermediate',
    '1',
    '2020-01-13',
    '2020-05-13'
  ),
  (
    '43',
    'ctd2-pancancer-chemosensitivity',
    'CTD2 Pancancer Chemosensitivity',
    '',
    'Over the last two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and molecular profiles representative of cellular responses to drug perturbations. PANACEA covers a broad ...',
    'https://www.synapse.org/#!Synapse:syn21763589',
    'completed',
    'good_for_beginners',
    '1',
    '2020-04-28',
    '2020-07-27'
  ),
  (
    '44',
    'ehr-covid-19',
    'EHR COVID-19',
    '',
    'The rapid rise of COVID-19 has challenged healthcare globally. The underlying risks and outcomes of infection are still incompletely characterized even as the world surpasses 4 million infections. Due to the importance and emergent need for better understanding of the condit...',
    'https://www.synapse.org/#!Synapse:syn21849255',
    'completed',
    'intermediate',
    '1',
    '2020-04-30',
    '2021-07-01'
  ),
  (
    '45',
    'anti-pd1-response-prediction',
    'Anti-PD1 Response Prediction',
    '',
    'While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy, there remains a need to improve the ability to predict which patients are more likely to receive benefit from treatment wi...',
    'https://www.synapse.org/#!Synapse:syn18404605',
    'completed',
    'intermediate',
    '1',
    '2020-11-17',
    '2021-02-25'
  ),
  (
    '46',
    'brats-2021-challenge',
    'BraTS 2021 Challenge',
    '',
    'Glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma), are the most common and aggressive malignant primary tumor of the central nervous system in adults, with extreme intrinsic heterogeneity in appearance, shape, and h...',
    'https://www.synapse.org/#!Synapse:syn25829067',
    'completed',
    'advanced',
    '1',
    '2021-07-07',
    '2021-10-15'
  ),
  (
    '47',
    'cancer-data-registry-nlp',
    'Cancer Data Registry NLP',
    '',
    'A critical bottleneck in translational and clinical research is access to large volumes of high-quality clinical data. While structured data exist in medical EHR systems, a large portion of patient information including patient status, treatments, and outcomes is contained i...',
    'https://www.synapse.org/#!Synapse:syn18361217',
    'upcoming',
    'intermediate',
    '1',
    NULL,
    NULL
  ),
  (
    '48',
    'barda-community-challenge-pediatric-covid-19-data-challenge',
    'BARDA Community Challenge - Pediatric COVID-19 Data Challenge',
    '',
    'While most children with COVID-19 are asymptomatic or have mild symptoms, healthcare providers have difficulty determining which among their pediatric patients will progress to moderate or severe COVID-19 early in the progression. Some of these patients develop multisystem i...',
    'https://www.synapse.org/#!Synapse:syn25875374/wiki/611225',
    'completed',
    'intermediate',
    '1',
    '2021-08-19',
    '2021-12-17'
  ),
  (
    '49',
    'brats-continuous-evaluation',
    'BraTS Continuous Evaluation',
    '',
    'Brain tumors are among the deadliest types of cancer. Specifically, glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma), are the most common and aggressive malignant primary tumor of the central nervous system in adul...',
    'https://www.synapse.org/#!Synapse:syn27046444/wiki/616571',
    'active',
    'advanced',
    '1',
    '2022-01-01',
    NULL
  ),
  (
    '50',
    'fets-2022',
    'FeTS 2022',
    '',
    'FeTS 2022 focuses on benchmarking methods for federated learning (FL), and particularly i) weight aggregation methods for federated training, and ii) algorithmic generalizability on out-of-sample data based on federated evaluation. In line with its last instance (FeTS 2021 -...',
    'https://www.synapse.org/#!Synapse:syn28546456/wiki/617093',
    'completed',
    'advanced',
    '1',
    '2022-04-08',
    '2022-08-15'
  ),
  (
    '51',
    'random-promotor',
    'Random Promotor',
    '',
    'Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in a process termed “cis-regulatory logic”, where proteins called Transcription Factors (TFs) bind to specific DNA sequences within the genome and work toget...',
    'https://www.synapse.org/#!Synapse:syn28469146/wiki/617075',
    'completed',
    'intermediate',
    '1',
    '2022-05-02',
    '2022-08-07'
  ),
  (
    '52',
    'preterm-birth-prediction-microbiome',
    'Preterm Birth Prediction - Microbiome',
    '',
    'Globally, about 11% of infants every year are born preterm, defined as birth prior to 37 weeks of gestation, totaling nearly 15 million births.(5) In addition to the emotional and financial toll on families, preterm births have higher rates of neonatal death, nearly 1 millio...',
    'https://www.synapse.org/#!Synapse:syn26133770/wiki/612541',
    'completed',
    'advanced',
    '1',
    '2022-07-19',
    '2022-09-16'
  ),
  (
    '53',
    'finrisk',
    'FINRISK - Heart Failure and Microbiome',
    '',
    'Cardiovascular diseases are the leading cause of death both in men and women worldwide. Heart failure (HF) is the most common form of heart disease, characterised by the heart''s inability to pump a sufficient supply of blood to meet the needs of the body. The lifetime risk ...',
    'https://www.synapse.org/#!Synapse:syn27130803/wiki/616705',
    'completed',
    'advanced',
    '1',
    '2022-09-20',
    '2023-01-30'
  ),
  (
    '54',
    'scrna-seq-and-scatac-seq-data-analysis',
    'scRNA-seq and scATAC-seq Data Analysis',
    '',
    'Understanding transcriptional regulation at individual cell resolution is fundamental to understanding complex biological systems such as tissues and organs. Emerging high-throughput sequencing technologies now allow for transcript quantification and chromatin accessibility ...',
    'https://www.synapse.org/#!Synapse:syn26720920/wiki/615338',
    'active',
    'advanced',
    '1',
    '2022-11-29',
    '2023-02-08'
  ),
  (
    '55',
    'cough-diagnostic-algorithm-for-tuberculosis',
    'COugh Diagnostic Algorithm for Tuberculosis',
    '',
    'Tuberculosis (TB), a communicable disease caused by Mycobacterium tuberculosis, is a major cause of ill health and one of the leading causes of death worldwide. Until the COVID-19 pandemic, TB was the leading cause of death from a single infectious agent, ranking even above ...',
    'https://www.synapse.org/#!Synapse:syn31472953/wiki/617828',
    'active',
    'advanced',
    '1',
    '2022-10-16',
    '2023-02-13'
  ),
  (
    '56',
    'nih-long-covid-computational-challenge',
    'NIH Long COVID Computational Challenge',
    '',
    'The overall prevalence of post-acute sequelae of SARS-CoV-2 (PASC) is currently unknown, but there is growing evidence that more than half of COVID-19 survivors experience at least one symptom of PASC/Long COVID at six months after recovery of the acute illness. Reports also...',
    'https://www.synapse.org/#!Synapse:syn33576900/wiki/618451',
    'completed',
    'intermediate',
    '1',
    '2022-08-25',
    '2022-12-15'
  ),
  (
    '57',
    'bridge2ai',
    'Bridge2AI',
    'What makes a good color palette?',
    'What makes a good color palette?',
    '',
    'upcoming',
    'good_for_beginners',
    '1',
    NULL,
    NULL
  ),
  (
    '58',
    'rare-x-open-data-science',
    'RARE-X Open Data Science',
    '',
    'The Xcelerate RARE: A Rare Disease Open Science Data Challenge is bringing together researchers and data scientists in a collaborative and competitive environment to make the best use of patient-provided data to solve big unknowns in healthcare. The Challenge will launch to ...',
    'https://www.synapse.org/#!Synapse:syn51198355/wiki/621435',
    'upcoming',
    'intermediate',
    '1',
    '2023-05-17',
    NULL
  ),
  (
    '59',
    'cagi5-regulation-saturation',
    'CAGI5: Regulation saturation',
    '',
    '17,500 single nucleotide variants (SNVs) in 5 human disease associated enhancers (including IRF4, IRF6, MYC, SORT1) and 9 promoters (including TERT, LDLR, F9, HBG1) were assessed in a saturation mutagenesis massively parallel reporter assay. Promoters were cloned into a plas...',
    'https://genomeinterpretation.org/cagi5-regulation-saturation.html',
    'completed',
    'intermediate',
    '2',
    '2018-01-04',
    '2018-05-03'
  ),
  (
    '60',
    'cagi5-calm1',
    'CAGI5: CALM1',
    '',
    'Calmodulin is a calcium-sensing protein that modulates the activity of a large number of proteins in the cell. It is involved in many cellular processes, and is especially important for neuron and muscle cell function. Variants that affect calmodulin function have been found...',
    'https://genomeinterpretation.org/cagi5-calm1.html',
    'completed',
    'intermediate',
    '2',
    '2017-10-21',
    '2017-12-20'
  ),
  (
    '61',
    'cagi5-pcm1',
    'CAGI5: PCM1',
    '',
    'The PCM1 (Pericentriolar Material 1) gene is a component of centriolar satellites occurring around centrosomes in vertebrate cells. Several studies have implicated PCM1 variants as a risk factor for schizophrenia. Ventricular enlargement is one of the most consistent abnorma...',
    'https://genomeinterpretation.org/cagi5-pcm1.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-09',
    '2018-04-19'
  ),
  (
    '62',
    'cagi5-frataxin',
    'CAGI5: Frataxin',
    '',
    'Fraxatin is a highly-conserved protein found in prokaryotes and eukaryotes that is required for efficient regulation of cellular iron homeostasis. Humans with a frataxin deficiency have the cardio- and neurodegenerative disorder Friedreich''s ataxia. A library of eight misse...',
    'https://genomeinterpretation.org/cagi5-frataxin.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-30',
    '2018-04-18'
  ),
  (
    '63',
    'cagi5-tpmt-and-p10',
    'CAGI5: TPMT and p10',
    '',
    'The gene p10 encodes for PTEN (Phosphatase and TEnsin Homolog), an important secondary messenger molecule promoting cell growth and survival through signaling cascades including those controlled by AKT and mTOR. Thiopurine S-methyl transferase (TPMT) is a key enzyme involved...',
    'https://genomeinterpretation.org/cagi5-tpmt.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-30',
    '2017-12-01'
  ),
  (
    '64',
    'cagi5-annotate-all-nonsynonymous-variants',
    'CAGI5: Annotate all nonsynonymous variants',
    '',
    'dbNSFP describes 810,848,49 possible protein-altering variants in the human genome. The challenge is to predict the functional effect of every such variant. For the vast majority of these missense variants, the functional impact is not currently known, but experimental and c...',
    'https://genomeinterpretation.org/cagi5-annotate-all-missense.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-30',
    '2018-05-09'
  ),
  (
    '65',
    'cagi5-gaa',
    'CAGI5: GAA',
    '',
    'Acid alpha-glucosidase (GAA) is a lysosomal alpha-glucosidase. Some mutations in GAA cause a rare disorder, Pompe disease, (Glycogen Storage Disease II). Rare GAA missense variants found in a human population sample have been assayed for enzymatic activity in transfected cel...',
    'https://genomeinterpretation.org/cagi5-gaa.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-09',
    '2018-04-25'
  ),
  (
    '66',
    'cagi5-chek2',
    'CAGI5: CHEK2',
    '',
    'Variants in the CHEK2 gene are associated with breast cancer. This challenge includes CHEK2 gene variants from approximately 1200 Latino breast cancer cases and 1200 ethnically matched controls. This challenge is to estimate the probability of each gene variant occurring in ...',
    'https://genomeinterpretation.org/cagi5-chek2.html',
    'completed',
    'intermediate',
    '2',
    '2017-12-20',
    '2018-04-24'
  ),
  (
    '67',
    'cagi5-enigma',
    'CAGI5: ENIGMA',
    '',
    'Breast cancer is the most prevalent cancer among women worldwide. The association between germline mutations in the BRCA1 and BRCA2 genes and the development of cancer has been well established. The most common high-risk mutations associated with breast cancer are those in t...',
    'https://genomeinterpretation.org/cagi5-enigma.html',
    'completed',
    'intermediate',
    '2',
    '2017-12-20',
    '2018-05-01'
  ),
  (
    '68',
    'cagi5-mapsy',
    'CAGI5: MaPSy',
    '',
    'The Massively Parallel Splicing Assay (MaPSy) approach was used to screen 797 reported exonic disease mutations using a mini-gene system, assaying both in vivo via transfection in tissue culture, and in vitro via incubation in cell nuclear extract. The challenge is to predic...',
    'https://genomeinterpretation.org/cagi5-mapsy.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-29',
    '2018-05-07'
  ),
  (
    '69',
    'cagi5-vex-seq',
    'CAGI5: Vex-seq',
    '',
    'A barcoding approach called Variant exon sequencing (Vex-seq) was applied to assess effect of 2,059 natural single nucleotide variants and short indels on splicing of a globin mini-gene construct transfected into HepG2 cells. This is reported as ΔΨ (delta PSI, or Percent Spl...',
    'https://genomeinterpretation.org/cagi5-vex-seq.html',
    'completed',
    'intermediate',
    '2',
    '2017-12-14',
    '2018-05-02'
  ),
  (
    '70',
    'cagi5-sickkids-clinical-genomes',
    'CAGI5: SickKids clinical genomes',
    '',
    'This challenge involves 30 children with suspected genetic disorders who were referred for clinical genome sequencing. Predictors are given the 30 genome sequences, and are also provided with the phenotypic descriptions as shared with the diagnostic laboratory. The challenge...',
    'https://genomeinterpretation.org/cagi5-sickkids5.html',
    'completed',
    'intermediate',
    '2',
    '2017-12-22',
    '2018-04-26'
  ),
  (
    '71',
    'cagi5-id-panel',
    'CAGI5: ID Panel',
    '',
    'The challenge presented here is to use computational methods to predict a patient’s clinical phenotype and the causal variant(s) based on analysis of their gene panel sequence data. Sequence data for 74 genes associated with intellectual disability (ID) and/or Autism spectru...',
    'https://genomeinterpretation.org/cagi5-intellectual-disability.html',
    'completed',
    'intermediate',
    '2',
    '2017-12-22',
    '2018-04-30'
  ),
  (
    '72',
    'cagi5-clotting-disease-exomes',
    'CAGI5: Clotting disease exomes',
    '',
    'African Americans have a higher incidence of developing venous thromboembolisms (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), than people of European ancestry. Participants are provided with exome data and clinical covariates for a cohort of A...',
    'https://genomeinterpretation.org/cagi5-clotting-disease.html',
    'completed',
    'intermediate',
    '2',
    '2017-11-23',
    '2018-04-28'
  ),
  (
    '73',
    'cagi6-rare-genomes-project',
    'CAGI6: Rare Genomes Project',
    '',
    'The Rare Genomes Project (RGP) is a direct-to-participant research study on the utility of genome sequencing for rare disease diagnosis and gene discovery. The study is led by genomics experts and clinicians at the Broad Institute of MIT and Harvard. Research subjects are co...',
    'https://genomeinterpretation.org/cagi6-rgp.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-10-11'
  ),
  (
    '74',
    'cagi6-intellectual-disability-panel',
    'CAGI6: Intellectual Disability Panel',
    '',
    'The objective in this challenge is to predict a patient’s clinical phenotype and the causal variant(s) based on their gene panel sequences. Sequence data for 74 genes from a cohort of 500 patients with a range of neurodevelopmental presentations (intellectual disability, aut...',
    'https://genomeinterpretation.org/cagi6-id-panel.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-10-11'
  ),
  (
    '75',
    'cagi6-sickkids-clinical-genomes-and-transcriptomes',
    'CAGI6: SickKids clinical genomes and transcriptomes',
    '',
    'This challenge involves data from 79 children who were referred to The Hospital for Sick Children’s (SickKids) Genome Clinic for genome sequencing because of suspected but undiagnosed genetic disorders. Research subjects are consented for sharing of their sequence data and p...',
    'https://genomeinterpretation.org/cagi6-sickkids.html',
    'completed',
    'intermediate',
    '1',
    '2021-08-04',
    '2021-12-31'
  ),
  (
    '76',
    'cagi6-polygenic-risk-scores',
    'CAGI6: Polygenic Risk Scores',
    '',
    'Polygenic risk scores (PRS) have potential clinical utility for risk surveillance, prevention and personalized medicine. Participants will be provided with datasets of four real phenotypes (Type 2 Diabetes, Breast Cancer, Inflammatory Bowel Disease and Coronary Artery Diseas...',
    'https://genomeinterpretation.org/cagi6-prs.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-10-11'
  ),
  (
    '77',
    'cagi6-hmbs',
    'CAGI6: HMBS',
    '',
    'Hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase (PBGD) or uroporphyrinogen I synthase, is an enzyme involved in heme production. In humans, variants that affect HMBS function result in acute intermittent porphyria (AIP), an autosomal dominant gen...',
    'https://genomeinterpretation.org/cagi6-hmbs.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-10-11'
  ),
  (
    '78',
    'cagi6-cam',
    'CAGI6: CaM',
    '',
    'Calmodulin (CaM) is a ubiquitous calcium (Ca2+) sensor protein interacting with more than 200 molecular partners, thereby regulating a variety of biological processes. Missense point mutations in the genes encoding CaM have been associated with ventricular tachycardia and su...',
    'https://genomeinterpretation.org/cagi6-cam.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-10-11'
  ),
  (
    '79',
    'cagi6-annotate-all-missense',
    'CAGI6: Annotate All Missense',
    '',
    'dbNSFP currently describes 81,782,923 possible protein-altering variants in the human genome. The challenge is to predict the functional effect of every such variant. For the vast majority of these missense and nonsense variants, the functional impact is not currently known,...',
    'https://genomeinterpretation.org/cagi6-annotate-all-missense.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-01',
    '2021-10-11'
  ),
  (
    '80',
    'cagi6-stk11',
    'CAGI6: STK11',
    '',
    'Serine/Threonine Kinase 11 (STK11) is considered a master kinase that functions as a tumor suppressor and nutrient sensor within a heterotrimeric complex with pseudo-kinase STRAD-alpha and structural protein MO25. Germline variants resulting in loss of STK11 define Peutz-Jag...',
    'https://genomeinterpretation.org/cagi6-stk11.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-09-01'
  ),
  (
    '81',
    'cagi6-mapk1',
    'CAGI6: MAPK1',
    '',
    'MAPK1 (ERK2) is active as serine/threonine kinase in the Ras-Raf-MEK-ERK signal transduction cascade that regulates cell proliferation, transcription, differentiation, and cell cycle progression. MAPK1 is activated by phosphorylation which occurs with strict specificity by M...',
    'https://genomeinterpretation.org/cagi6-mapk1.html',
    'completed',
    'intermediate',
    '1',
    '2021-07-08',
    '2021-10-11'
  ),
  (
    '82',
    'cagi6-mapk3',
    'CAGI6: MAPK3',
    '',
    'MAPK3 (ERK1) is active as serine/threonine kinase in the Ras-Raf-MEK-ERK signal transduction cascade that regulates cell proliferation, transcription, differentiation, and cell cycle progression. MAPK3 is activated by phosphorylation which occurs with strict specificity by M...',
    'https://genomeinterpretation.org/cagi6-mapk3.html',
    'completed',
    'intermediate',
    '1',
    '2021-08-04',
    '2021-10-11'
  ),
  (
    '83',
    'cagi6-mthfr',
    'CAGI6: MTHFR',
    '',
    'Methylenetetrahydrofolate reductase (MTHFR) catalyzes the production of 5-methyltetrahydrofolate, which is needed for conversion of homocysteine to methionine. Humans with variants affecting MTHFR function present with a wide range of phenotypes, including homocystinuria, ho...',
    'https://genomeinterpretation.org/cagi6-mthfr.html',
    'completed',
    'intermediate',
    '1',
    '2021-05-03',
    '2021-06-30'
  ),
  (
    '84',
    'cagi6-splicing-vus',
    'CAGI6: Splicing VUS',
    '',
    'Variants causing aberrant splicing have been implicated in a range of common and rare disorders, including retinitis pigmentosa, autism spectrum disorder, amyotrophic lateral sclerosis, and a variety of cancers. However, such variants are frequently overlooked by diagnostic ...',
    'https://genomeinterpretation.org/cagi6-splicing-vus.html',
    'completed',
    'intermediate',
    '1',
    '2021-06-08',
    '2021-10-11'
  ),
  (
    '85',
    'cagi6-sherloc-clinical-classification',
    'CAGI6: Sherloc clinical classification',
    '',
    'Invitae is a genetic testing company that publishes their variant interpretations to ClinVar. In this challenge, over 122,000 previously uncharacterized variants are provided, spanning the range of effects seen in the clinic. Following the close of this challenge, Invitae wi...',
    'https://genomeinterpretation.org/cagi6-invitae.html',
    'completed',
    'intermediate',
    '1',
    '2021-07-08',
    '2021-12-01'
  ),
  (
    '86',
    'cami-ii',
    'CAMI II',
    '',
    'CAMI II offers several challenges: an assembly, a genome binning, a taxonomic binning and a taxonomic profiling challenge, on several multi-sample data sets from different environments, including long and short read data. This includes a marine data set and a high-strain div...',
    'https://www.microbiome-cosi.org/cami/cami/cami2',
    'completed',
    'intermediate',
    '3',
    '2019-01-14',
    '2021-01-31'
  ),
  (
    '87',
    'camda18-metasub-forensics',
    'CAMDA18: MetaSUB Forensics',
    '',
    'The MetaSUB International Consortium is building a longitudinal metagenomic map of mass-transit systems and other public spaces across the globe. The consortium maintains a strategic partnership with CAMDA and this year provides data from global City Sampling Days for the fi...',
    'http://camda2018.bioinf.jku.at/doku.php/contest_dataset#metasub_forensics_challenge',
    'completed',
    'intermediate',
    '7',
    NULL,
    NULL
  ),
  (
    '88',
    'camda18-cmap-drug-safety',
    'CAMDA18: CMap Drug Safety',
    '',
    'Attrition in drug discovery and development due to safety / toxicity issues remains a significant concern, and there are strong efforts to identify and mitigate risk as early as possible. Drug-induced liver injury (DILI) is one of the primary problems in drug development and...',
    'http://camda2018.bioinf.jku.at/doku.php/contest_dataset#cmap_drug_safety_challenge',
    'completed',
    'intermediate',
    '7',
    NULL,
    NULL
  ),
  (
    '89',
    'camda18-cancer-data-integration',
    'CAMDA18: Cancer Data Integration',
    '',
    'Examine the power of data integration in a real-world clinical settings. Many approaches work well on some data-sets yet not on others. We here challenge you to demonstrate a unified single approach to data-integration that matches or outperforms the current state of the art...',
    'http://camda2018.bioinf.jku.at/doku.php/contest_dataset#cancer_data_integration_challenge',
    'completed',
    'intermediate',
    '7',
    NULL,
    NULL
  ),
  (
    '90',
    'cafa-4',
    'CAFA 4',
    '',
    'The goal of the Critical Assessment of Functional Annotation(CAFA) challenge is to evaluate automated protein function prediction algorithms in the task of predicting Gene Ontology and Human Phenotype Ontology terms for a given set of protein sequences. For the GO-based pred...',
    'https://www.biofunctionprediction.org/cafa/',
    'completed',
    'intermediate',
    '1',
    '2019-10-21',
    '2020-02-12'
  ),
  (
    '91',
    'casp13',
    'CASP13',
    '',
    'CASP (Critical Assessment of Structure Prediction) is a community wide experiment to determine and advance the state of the art in modeling protein structure from amino acid sequence. Every two years, participants are invited to submit models for a set of proteins for which ...',
    'https://predictioncenter.org/casp13/index.cgi',
    'completed',
    'intermediate',
    '4',
    '2018-04-18',
    '2018-08-20'
  ),
  (
    '92',
    'casp14',
    'CASP14',
    '',
    'CASP (Critical Assessment of Structure Prediction) is a community wide experiment to determine and advance the state of the art in modeling protein structure from amino acid sequence. Every two years, participants are invited to submit models for a set of proteins for which ...',
    'https://predictioncenter.org/casp14/index.cgi',
    'completed',
    'intermediate',
    '4',
    '2020-05-04',
    '2020-09-07'
  ),
  (
    '93',
    'cfsan-pathogen-detection',
    'CFSAN Pathogen Detection',
    '',
    'In the U.S. alone, one in six individuals, an estimated 48 million people, fall prey to foodborne illness, resulting in 128,000 hospitalizations and 3,000 deaths per year. Economic burdens are estimated cumulatively at $152 billion dollars annually, including $39 billion due...',
    'https://precision.fda.gov/challenges/2',
    'completed',
    'intermediate',
    '6',
    '2018-02-15',
    '2018-04-26'
  ),
  (
    '94',
    'cdrh-biothreat',
    'CDRH Biothreat',
    '',
    'Many infectious diseases have similar signs and symptoms, making it challenging for healthcare providers to identify the disease-causing agent. Clinical samples are often tested by multiple test methods to help reveal the microbe that is causing the infectious disease. The r...',
    'https://precision.fda.gov/challenges/3',
    'completed',
    'intermediate',
    '6',
    '2018-08-03',
    '2018-10-18'
  ),
  (
    '95',
    'multi-omics-enabled-sample-mislabeling-correction',
    'Multi-omics Enabled Sample Mislabeling Correction',
    '',
    'In biomedical research, sample mislabeling (accidental swapping of patient samples) or data mislabeling (accidental swapping of patient omics data) has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particu...',
    'https://precision.fda.gov/challenges/4',
    'completed',
    'intermediate',
    '6',
    '2018-09-24',
    '2018-12-19'
  ),
  (
    '96',
    'biocompute-object-app-a-thon',
    'BioCompute Object App-a-thon',
    '',
    'Like scientific laboratory experiments, bioinformatics analysis results and interpretation are faced with reproducibility challenges due to the variability in multiple computational parameters, including input format, prerequisites, platform dependencies, and more. Even smal...',
    'https://precision.fda.gov/challenges/7/',
    'completed',
    'intermediate',
    '6',
    '2019-05-14',
    '2019-10-18'
  ),
  (
    '97',
    'brain-cancer-predictive-modeling-and-biomarker-discovery',
    'Brain Cancer Predictive Modeling and Biomarker Discovery',
    '',
    'An estimated 86,970 new cases of primary brain and other central nervous system tumors are expected to be diagnosed in the US in 2019. Brain tumors comprise a particularly deadly subset of all cancers due to limited treatment options and the high cost of care. Only a few pro...',
    'https://precision.fda.gov/challenges/8/',
    'completed',
    'advanced',
    '6',
    '2019-11-01',
    '2020-02-14'
  ),
  (
    '98',
    'gaining-new-insights-by-detecting-adverse-event-anomalies',
    'Gaining New Insights by Detecting Adverse Event Anomalies',
    '',
    'The Food and Drug Administration (FDA) calls on the public to develop computational algorithms for automatic detection of adverse event anomalies using publicly available data.',
    'https://precision.fda.gov/challenges/9/',
    'completed',
    'intermediate',
    '6',
    '2020-01-17',
    '2020-05-18'
  ),
  (
    '99',
    'calling-variants-in-difficult-to-map-regions',
    'Calling Variants in Difficult-to-Map Regions',
    '',
    'This challenge calls on the public to assess variant calling pipeline performance on a common frame of reference, with a focus on benchmarking in difficult-to-map regions, segmental duplications, and the Major Histocompatibility Complex (MHC).',
    'https://precision.fda.gov/challenges/10/',
    'completed',
    'intermediate',
    '6',
    '2020-05-01',
    '2020-06-15'
  ),
  (
    '100',
    'vha-innovation-ecosystem-and-covid-19-risk-factor-modeling',
    'VHA Innovation Ecosystem and COVID-19 Risk Factor Modeling',
    '',
    'The novel coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2,” or SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandem...',
    'https://precision.fda.gov/challenges/11/',
    'completed',
    'intermediate',
    '6',
    '2020-06-02',
    '2020-07-03'
  ),
  (
    '101',
    'covid-19-precision-immunology-app-a-thon',
    'COVID-19 Precision Immunology App-a-thon',
    '',
    'The novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2” or SARS-CoV-2, was declared a global pandemic by the World Health Organization on March 11, 2020. To date, the...',
    'https://precision.fda.gov/challenges/12/',
    'completed',
    'intermediate',
    '6',
    '2020-11-30',
    '2021-01-29'
  ),
  (
    '102',
    'smarter-food-safety-low-cost-tech-enabled-traceability',
    'Smarter Food Safety Low Cost Tech-Enabled Traceability',
    '',
    'The motivation is tapping into new technologies and integrating data streams will help to advance the widespread, consistent implementation of traceability systems across the food industry. However, the affordability of such technologies, particularly for smaller companies, ...',
    'https://precision.fda.gov/challenges/13',
    'completed',
    'intermediate',
    '6',
    '2021-06-01',
    '2021-07-30'
  ),
  (
    '103',
    'tumor-mutational-burden-tmb-challenge-phase-1',
    'Tumor Mutational Burden (TMB) Challenge Phase 1',
    '',
    'Tumor mutational burden (TMB) is generally defined as the number of mutations detected in a patient’s tumor sample per megabase of DNA sequenced. However different algorithms use different methods for calculating TMB. Mutations in genes in tumor cells may lead to the creatio...',
    'https://precision.fda.gov/challenges/17',
    'completed',
    'advanced',
    '6',
    '2021-06-21',
    '2021-09-13'
  ),
  (
    '104',
    'kidney-and-kidney-tumor-segmentation',
    'Kidney and Kidney Tumor Segmentation',
    '',
    'The 2021 Kidney and Kidney Tumor Segmentation challenge (abbreviated KiTS21) is a competition in which teams compete to develop the best system for automatic semantic segmentation of renal tumors and surrounding anatomy. Kidney cancer is one of the most common malignancies i...',
    'https://kits21.kits-challenge.org/',
    'completed',
    'advanced',
    '5',
    '2021-08-23',
    '2021-09-17'
  ),
  (
    '105',
    'cross-modality-da-for-medical-image-segmentation',
    'Cross-Modality DA for Medical Image Segmentation',
    '',
    'Domain Adaptation (DA) has recently raised strong interests in the medical imaging community. By encouraging algorithms to be robust to unseen situations or different input data domains, Domain Adaptation improves the applicability of machine learning approaches to various c...',
    'https://crossmoda-challenge.ml/',
    'completed',
    'advanced',
    '5',
    '2021-04-05',
    '2021-09-27'
  ),
  (
    '106',
    'real-noise-mri',
    'Real Noise MRI',
    '',
    'In recent years, there is a growing focus on the application of fast magnetic resonance imaging (MRI) based on prior knowledge. In the 1980s and 2000s the community used either purely mathematical models such as the partial Fourier transform or solutions derived through adva...',
    'https://realnoisemri.grand-challenge.org/Description/',
    'completed',
    'intermediate',
    '5',
    '2021-09-21',
    '2021-12-06'
  ),
  (
    '107',
    'deep-generative-model-challenge-for-da-in-surgery',
    'Deep Generative Model Challenge for DA in Surgery',
    '',
    'Mitral regurgitation (MR) is the second most frequent indication for valve surgery in Europe and may occur for organic or functional causes [1]. Mitral valve repair, although considerably more difficult, is prefered over mitral valve replacement, since the native tissue of t...',
    'https://adaptor2021.github.io/',
    'completed',
    'intermediate',
    '1',
    '2021-04-01',
    '2021-07-16'
  ),
  (
    '108',
    'aimdatathon',
    'AIM Datathon 2020',
    'Join the AI in Medicine ( AIM ) Datathon 2020',
    'Join the AI in Medicine ( AIM ) Datathon 2020',
    'https://www.kaggle.com/competitions/aimdatathon',
    'completed',
    'intermediate',
    '8',
    '2020-11-09',
    '2020-11-22'
  ),
  (
    '109',
    'opc-recurrence',
    'Oropharynx Cancer (OPC) Radiomics Challenge :: Local Recurrence Prediction',
    'Determine from CT data whether a tumor will be controlled by definitive radiatio',
    'Determine from CT data whether a tumor will be controlled by definitive radiation therapy.',
    'https://www.kaggle.com/competitions/opc-recurrence',
    'completed',
    'intermediate',
    '8',
    '2016-07-26',
    '2016-09-12'
  ),
  (
    '110',
    'oropharynx-radiomics-hpv',
    'Oropharynx Cancer (OPC) Radiomics Challenge :: Human Papilloma Virus (HPV) Status Prediction',
    'Predict from CT data the HPV phenotype of oropharynx tumors; compare to ground-t',
    'Predict from CT data the HPV phenotype of oropharynx tumors; compare to ground-truth results previously obtained by p16 or HPV testing.',
    'https://www.kaggle.com/competitions/oropharynx-radiomics-hpv',
    'completed',
    'intermediate',
    '8',
    '2016-07-26',
    '2016-09-12'
  ),
  (
    '111',
    'data-science-bowl-2017',
    'Data Science Bowl 2017',
    'Can you improve lung cancer detection?',
    'Can you improve lung cancer detection?',
    'https://www.kaggle.com/competitions/data-science-bowl-2017',
    'completed',
    'intermediate',
    '8',
    '2017-01-12',
    '2017-04-12'
  ),
  (
    '112',
    'predict-impact-of-air-quality-on-death-rates',
    'Predict impact of air quality on mortality rates',
    'Predict CVD and cancer caused mortality rates in England using air quality data ',
    'Predict CVD and cancer caused mortality rates in England using air quality data available from Copernicus Atmosphere Monitoring Service',
    'https://www.kaggle.com/competitions/predict-impact-of-air-quality-on-death-rates',
    'completed',
    'intermediate',
    '8',
    '2017-02-13',
    '2017-05-05'
  ),
  (
    '113',
    'intel-mobileodt-cervical-cancer-screening',
    'Intel & MobileODT Cervical Cancer Screening',
    'Which cancer treatment will be most effective?',
    'Which cancer treatment will be most effective?',
    'https://www.kaggle.com/competitions/intel-mobileodt-cervical-cancer-screening',
    'completed',
    'intermediate',
    '8',
    '2017-03-15',
    '2017-06-21'
  ),
  (
    '114',
    'msk-redefining-cancer-treatment',
    'Personalized Medicine: Redefining Cancer Treatment',
    'Predict the effect of Genetic Variants to enable Personalized Medicine',
    'Predict the effect of Genetic Variants to enable Personalized Medicine',
    'https://www.kaggle.com/competitions/msk-redefining-cancer-treatment',
    'completed',
    'intermediate',
    '8',
    '2017-06-26',
    '2017-10-02'
  ),
  (
    '115',
    'mubravo',
    'Predicting Cancer Diagnosis',
    'Bravo''s machine learning competition!',
    'Bravo''s machine learning competition!',
    'https://www.kaggle.com/competitions/mubravo',
    'completed',
    'intermediate',
    '8',
    '2018-07-31',
    '2018-08-13'
  ),
  (
    '116',
    'histopathologic-cancer-detection',
    'Histopathologic Cancer Detection',
    'Identify metastatic tissue in histopathologic scans of lymph node sections',
    'Identify metastatic tissue in histopathologic scans of lymph node sections',
    'https://www.kaggle.com/competitions/histopathologic-cancer-detection',
    'completed',
    'intermediate',
    '8',
    '2018-11-16',
    '2019-03-30'
  ),
  (
    '117',
    'tjml1920-decision-trees',
    'TJML 2019-20 Breast Cancer Detection Competition',
    'Use a decision tree to identify malignant breast cancer tumors',
    'Use a decision tree to identify malignant breast cancer tumors',
    'https://www.kaggle.com/competitions/tjml1920-decision-trees',
    'completed',
    'intermediate',
    '8',
    '2019-09-22',
    '2019-10-16'
  ),
  (
    '118',
    'prostate-cancer-grade-assessment',
    'Prostate cANcer graDe Assessment (PANDA) Challenge',
    'Prostate cancer diagnosis using the Gleason grading system',
    'Prostate cancer diagnosis using the Gleason grading system',
    'https://www.kaggle.com/competitions/prostate-cancer-grade-assessment',
    'completed',
    'intermediate',
    '8',
    '2020-04-21',
    '2020-07-22'
  ),
  (
    '119',
    'breast-cancer',
    'Breast Cancer',
    'Use cell nuclei categories to predict breast cancer tumor.',
    'Use cell nuclei categories to predict breast cancer tumor.',
    'https://www.kaggle.com/competitions/breast-cancer',
    'completed',
    'intermediate',
    '8',
    '2020-08-12',
    '2020-08-13'
  ),
  (
    '120',
    'breast-cancer-detection',
    'Breast Cancer Detection',
    'breast cancer detection',
    'breast cancer detection',
    'https://www.kaggle.com/competitions/breast-cancer-detection',
    'completed',
    'intermediate',
    '8',
    '2020-09-25',
    '2020-12-31'
  ),
  (
    '121',
    'hrpred',
    'Prediction of High Risk Patients',
    'Classification of high and low risk cancer patients',
    'Classification of high and low risk cancer patients',
    'https://www.kaggle.com/competitions/hrpred',
    'completed',
    'intermediate',
    '8',
    '2020-11-25',
    '2020-12-05'
  ),
  (
    '122',
    'ml4moleng-cancer',
    'MIT ML4MolEng: Predicting Cancer Progression',
    'MIT 3.100, 10.402, 20.301 In class ML competition (Spring 2021)',
    'MIT 3.100, 10.402, 20.301 In class ML competition (Spring 2021)',
    'https://www.kaggle.com/competitions/ml4moleng-cancer',
    'completed',
    'intermediate',
    '8',
    '2021-05-06',
    '2021-05-21'
  ),
  (
    '123',
    'uw-madison-gi-tract-image-segmentation',
    'UW-Madison GI Tract Image Segmentation',
    'Track healthy organs in medical scans to improve cancer treatment',
    'Track healthy organs in medical scans to improve cancer treatment',
    'https://www.kaggle.com/competitions/uw-madison-gi-tract-image-segmentation',
    'completed',
    'intermediate',
    '8',
    '2022-04-14',
    '2022-07-14'
  ),
  (
    '124',
    'rsna-miccai-brain-tumor-radiogenomic-classification',
    'RSNA-MICCAI Brain Tumor Radiogenomic Classification',
    'Predict the status of a genetic biomarker important for brain cancer treatment',
    'The Brain Tumor Segmentation (BraTS) challenge celebrates its 10th anniversary, and this year is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interv...',
    'https://www.kaggle.com/competitions/rsna-miccai-brain-tumor-radiogenomic-classification',
    'completed',
    'advanced',
    '8',
    '2021-07-13',
    '2021-10-15'
  ),
  (
    '125',
    'breastcancer',
    'Breast Cancer - Beginners ML',
    'Beginners hands-on experience with ML basics',
    'Beginners hands-on experience with ML basics',
    'https://www.kaggle.com/competitions/breastcancer',
    'completed',
    'intermediate',
    '8',
    '2021-12-21',
    '2022-02-12'
  ),
  (
    '126',
    'ml-olympiad-health-and-education',
    'ML Olympiad - Let''s Fight lung cancer',
    'Use your ML expertise to help us step another step toward defeating cancer [ Sta',
    'Use your ML expertise to help us step another step toward defeating cancer [ Starts on the 14th February ]',
    'https://www.kaggle.com/competitions/ml-olympiad-health-and-education',
    'completed',
    'intermediate',
    '8',
    '2022-01-31',
    '2022-03-19'
  ),
  (
    '127',
    'cs98-22-dl-task1',
    'CS98X-22-DL-Task1',
    'This competition is related to Task 1 in coursework - breast cancer classificati',
    'This competition is related to Task 1 in coursework - breast cancer classification',
    'https://www.kaggle.com/competitions/CS98-22-DL-Task1',
    'completed',
    'intermediate',
    '8',
    '2022-02-28',
    '2022-04-11'
  ),
  (
    '128',
    'parasitedetection-iiitb2019',
    'Parasite detection',
    'detect if cell image has parasite or is uninfected',
    'detect if cell image has parasite or is uninfected',
    'https://www.kaggle.com/competitions/parasitedetection-iiitb2019',
    'completed',
    'intermediate',
    '8',
    '2019-10-13',
    '2019-11-25'
  ),
  (
    '129',
    'hpa-single-cell-image-classification',
    'Human Protein Atlas - Single Cell Classification',
    'Find individual human cell differences in microscope images',
    'Find individual human cell differences in microscope images',
    'https://www.kaggle.com/competitions/hpa-single-cell-image-classification',
    'completed',
    'intermediate',
    '8',
    '2021-01-26',
    '2021-05-11'
  ),
  (
    '130',
    'stem-cell-predcition',
    'Stem Cell Predcition',
    'Classify stem and non-stem cells using RNA-seq data',
    'Classify stem and non-stem cells using RNA-seq data',
    'https://www.kaggle.com/competitions/stem-cell-predcition',
    'completed',
    'intermediate',
    '8',
    '2021-04-01',
    '2021-07-01'
  ),
  (
    '131',
    'sartorius-cell-instance-segmentation',
    'Sartorius - Cell Instance Segmentation',
    'Detect single neuronal cells in microscopy images',
    'Detect single neuronal cells in microscopy images',
    'https://www.kaggle.com/competitions/sartorius-cell-instance-segmentation',
    'completed',
    'intermediate',
    '8',
    '2021-10-14',
    '2021-12-30'
  ),
  (
    '132',
    'pvelad',
    'Photovoltaic cell anomaly detection',
    'Hosted by Hebei University of Technology (AIHebut research group) and Beihang Un',
    'Hosted by Hebei University of Technology (AIHebut research group) and Beihang University (NAVE research group)',
    'https://www.kaggle.com/competitions/pvelad',
    'completed',
    'intermediate',
    '8',
    '2022-03-15',
    '2022-07-30'
  ),
  (
    '133',
    'blood-mnist',
    'Blood-MNIST',
    'Classifying blood cell types using Weights and Biases',
    'Classifying blood cell types using Weights and Biases',
    'https://www.kaggle.com/competitions/blood-mnist',
    'completed',
    'intermediate',
    '8',
    '2022-03-19',
    '2022-03-19'
  ),
  (
    '134',
    'insilicomolhack',
    'MolHack',
    'Apply deep learning to speedup drug validation',
    'Apply deep learning to speedup drug validation',
    'https://www.kaggle.com/competitions/insilicomolhack',
    'completed',
    'intermediate',
    '8',
    '2018-04-02',
    '2018-05-25'
  ),
  (
    '135',
    'codata2019challenge',
    'Cell Response Classification',
    'From recorded timeseries of many cells in a well, predict which drug treatment h',
    'From recorded timeseries of many cells in a well, predict which drug treatment has been applied',
    'https://www.kaggle.com/competitions/codata2019challenge',
    'completed',
    'intermediate',
    '8',
    '2019-04-08',
    '2019-05-07'
  ),
  (
    '136',
    'drug-solubility-challenge',
    'Drug solubility challenge',
    'Solubility is vital to achieve desired concentration of drug for anticipated pha',
    'Solubility is vital to achieve desired concentration of drug for anticipated pharmacological response.',
    'https://www.kaggle.com/competitions/drug-solubility-challenge',
    'completed',
    'intermediate',
    '8',
    '2019-05-18',
    '2019-10-18'
  ),
  (
    '137',
    'kinase-inhibition-challenge',
    'Kinase inhibition challenge',
    'Protein kinases have become a major class of drug targets, accumulating a huge a',
    'Protein kinases have become a major class of drug targets, accumulating a huge amount of data',
    'https://www.kaggle.com/competitions/kinase-inhibition-challenge',
    'completed',
    'intermediate',
    '8',
    '2019-05-20',
    '2019-12-28'
  ),
  (
    '138',
    'ai-drug-discovery',
    'AI Drug Discovery Workshop and Coding Challenge',
    'Developing Fundamental AI Programming Skills for Drug Discovery',
    'Developing Fundamental AI Programming Skills for Drug Discovery',
    'https://www.kaggle.com/competitions/ai-drug-discovery',
    'completed',
    'intermediate',
    '8',
    '2021-11-12',
    '2021-12-31'
  ),
  (
    '139',
    'protein-compound-affinity',
    'Structure-free protein-ligand affinity prediction - Task 1 Fitting',
    'Developing new AI models for drug discovery, main portal (Task-1 fitting)',
    'Developing new AI models for drug discovery, main portal (Task-1 fitting)',
    'https://www.kaggle.com/competitions/protein-compound-affinity',
    'completed',
    'intermediate',
    '8',
    '2021-12-06',
    '2021-12-31'
  ),
  (
    '140',
    'cisc873-dm-f21-a5',
    'CISC873-DM-F21-A5',
    'Anti-Cancer Drug Activity Prediction',
    'Anti-Cancer Drug Activity Prediction',
    'https://www.kaggle.com/competitions/cisc873-dm-f21-a5',
    'completed',
    'intermediate',
    '8',
    '2021-11-26',
    '2021-12-10'
  ),
  (
    '141',
    'pro-lig-aff-task2-mse',
    'Structure-free protein-ligand affinity prediction - Task 2 Fitting',
    'Developing new AI models for drug discovery (Task-2 fitting)',
    'Developing new AI models for drug discovery (Task-2 fitting)',
    'https://www.kaggle.com/competitions/pro-lig-aff-task2-mse',
    'completed',
    'intermediate',
    '8',
    '2021-12-08',
    '2021-12-31'
  ),
  (
    '142',
    'pro-lig-aff-task1-pearsonr',
    'Structure-free protein-ligand affinity prediction - Task 1 Ranking',
    'Developing new AI models for drug discovery (Task-1 ranking)',
    'Developing new AI models for drug discovery (Task-1 ranking)',
    'https://www.kaggle.com/competitions/pro-lig-aff-task1-pearsonr',
    'completed',
    'intermediate',
    '8',
    '2021-12-08',
    '2021-12-31'
  ),
  (
    '143',
    'pro-lig-aff-task2-pearsonr',
    'Structure-free protein-ligand affinity prediction - Task 2 Ranking',
    'Developing new AI models for drug discovery (Task-2 ranking)',
    'Developing new AI models for drug discovery (Task-2 ranking)',
    'https://www.kaggle.com/competitions/pro-lig-aff-task2-pearsonr',
    'completed',
    'intermediate',
    '8',
    '2021-12-08',
    '2021-12-31'
  ),
  (
    '144',
    'pro-lig-aff-task3-spearmanr',
    'Structure-free protein-ligand affinity prediction - Task 3 Ranking',
    'Developing new AI models for drug discovery (Task-3 ranking)',
    'Developing new AI models for drug discovery (Task-3 ranking)',
    'https://www.kaggle.com/competitions/pro-lig-aff-task3-spearmanr',
    'completed',
    'intermediate',
    '8',
    '2021-12-08',
    '2021-12-31'
  ),
  (
    '145',
    'hhp',
    'Heritage Health Prize',
    'Identify patients who will be admitted to a hospital within the next year using ',
    'Identify patients who will be admitted to a hospital within the next year using historical claims data. (Enter by 06:59:59 UTC Oct 4 2012)',
    'https://www.kaggle.com/competitions/hhp',
    'completed',
    'intermediate',
    '8',
    '2011-04-04',
    '2013-04-04'
  ),
  (
    '146',
    'pf2012',
    'Practice Fusion Analyze This! 2012 - Prediction Challenge',
    'Start digging into electronic health records and submit your ideas for the most ',
    'Start digging into electronic health records and submit your ideas for the most promising, impactful or interesting predictive modeling competitions',
    'https://www.kaggle.com/competitions/pf2012',
    'completed',
    'intermediate',
    '8',
    '2012-06-07',
    '2012-06-30'
  ),
  (
    '147',
    'pf2012-at',
    'Practice Fusion Analyze This! 2012 - Open Challenge',
    'Start digging into electronic health records and submit your creative, insightfu',
    'Start digging into electronic health records and submit your creative, insightful, and visually striking analyses.',
    'https://www.kaggle.com/competitions/pf2012-at',
    'completed',
    'intermediate',
    '8',
    '2012-06-07',
    '2012-09-10'
  ),
  (
    '148',
    'seizure-detection',
    'UPenn and Mayo Clinic''s Seizure Detection Challenge',
    'Detect seizures in intracranial EEG recordings',
    'Detect seizures in intracranial EEG recordings',
    'https://www.kaggle.com/competitions/seizure-detection',
    'completed',
    'intermediate',
    '8',
    '2014-05-19',
    '2014-08-19'
  ),
  (
    '149',
    'seizure-prediction',
    'American Epilepsy Society Seizure Prediction Challenge',
    'Predict seizures in intracranial EEG recordings',
    'Predict seizures in intracranial EEG recordings',
    'https://www.kaggle.com/competitions/seizure-prediction',
    'completed',
    'intermediate',
    '8',
    '2014-08-25',
    '2014-11-17'
  ),
  (
    '150',
    'deephealth-1',
    'Deep Health - alcohol',
    'Find Correlations and patterns with Medical data',
    'Find Correlations and patterns with Medical data',
    'https://www.kaggle.com/competitions/deephealth-1',
    'completed',
    'intermediate',
    '8',
    '2017-02-13',
    '2017-02-19'
  ),
  (
    '151',
    'deep-health-3',
    'Deep Health - Diabetes 2',
    'This competition is for those attending the Deep Health Hackathon.  Predict the ',
    'This competition is for those attending the Deep Health Hackathon.  Predict the next occurrence of diabetes',
    'https://www.kaggle.com/competitions/deep-health-3',
    'completed',
    'intermediate',
    '8',
    '2017-02-15',
    '2017-02-19'
  ),
  (
    '152',
    'd012554-2021',
    'D012554 - 2021',
    'Classify the health of a fetus using CTG data',
    'Classify the health of a fetus using CTG data',
    'https://www.kaggle.com/competitions/d012554-2021',
    'completed',
    'intermediate',
    '8',
    '2021-04-11',
    '2021-05-09'
  ),
  (
    '153',
    'idao-2022-bootcamp-insomnia',
    'IDAO 2022. ML Bootcamp - Insomnia',
    'Predict sleep disorder on given human health data',
    'Predict sleep disorder on given human health data',
    'https://www.kaggle.com/competitions/idao-2022-bootcamp-insomnia',
    'completed',
    'intermediate',
    '8',
    '2021-12-04',
    '2021-12-05'
  ),
  (
    '154',
    'tweet-mental-health-classification',
    'Tweet Mental Health Classification',
    'Build Models to classify tweets to determine mental health',
    'Build Models to classify tweets to determine mental health',
    'https://www.kaggle.com/competitions/tweet-mental-health-classification',
    'completed',
    'intermediate',
    '8',
    '2021-12-27',
    '2022-01-31'
  ),
  (
    '155',
    'ml-olympiad-good-health-and-well-being',
    'ML Olympiad - GOOD HEALTH AND WELL BEING',
    'Use your ML expertise to classify if a patient has heart disease or not',
    'Use your ML expertise to classify if a patient has heart disease or not',
    'https://www.kaggle.com/competitions/ml-olympiad-good-health-and-well-being',
    'completed',
    'intermediate',
    '8',
    '2022-02-03',
    '2022-03-01'
  ),
  (
    '156',
    'rsna-breast-cancer-detection',
    'RSNA Screening Mammography Breast Cancer Detection',
    'Find breast cancers in screening mammograms',
    'Find breast cancers in screening mammograms',
    'https://www.kaggle.com/competitions/rsna-breast-cancer-detection',
    'active',
    'intermediate',
    '8',
    '2022-11-28',
    '2023-02-27'
  ),
  (
    '157',
    'biocreative-vii-text-mining-drug-and-chemical-protein-interactions-drugprot',
    'BioCreative VII: Text mining drug and chemical-protein interactions (DrugProt)',
    '',
    'With the rapid accumulation of biomedical literature, it is getting increasingly challenging to exploit efficiently drug-related information described in the scientific literature. One of the most relevant aspects of drugs and chemical compounds are their relationships with ...',
    'https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vii/track-1/',
    'completed',
    'intermediate',
    '7',
    '2021-06-15',
    '2021-09-22'
  ),
  (
    '158',
    'extended-literature-ai-for-drug-induced-liver-injury',
    'Extended Literature AI for Drug Induced Liver Injury',
    '',
    'Unexpected Drug-Induced Liver Injury (DILI) still is one of the main killers of promising novel drug candidates. It is a clinically significant disease that can lead to severe outcomes such as acute liver failure and even death. It remains one of the primary liabilities in d...',
    'http://camda2022.bioinf.jku.at/contest_dataset#extended_literature_ai_for_drug_induced_liver_injury',
    'completed',
    'intermediate',
    '7',
    NULL,
    '2022-05-20'
  ),
  (
    '159',
    'anti-microbial-resistance-forensics',
    'Anti-Microbial Resistance Forensics',
    '',
    'Bacteriophages, being the re-occuring mystery in the history of science are believed to be they key for understanding of microbial evolution and the transfer of AMR genes. Recent studies show that there is a significant correlation between occurence of Phages and AMR genes, ...',
    'http://camda2022.bioinf.jku.at/contest_dataset#anti-microbial_resistance_forensics',
    'completed',
    'intermediate',
    '7',
    NULL,
    '2022-05-20'
  ),
  (
    '160',
    'disease-maps-to-modelling-covid-19',
    'Disease Maps to Modelling COVID-19',
    'Use the COVID-19 disease map to suggest drugs candidate for repurposing, that co',
    'The Disease Maps to modeling COVID-19 Challenge provides highly detailed expert-curated molecular mechanistic maps for COVID-19. Combine them with available omic data to expand the current biological knowledge on COVID-19 mechanism of infection and downstream consequences. T...',
    'http://camda2022.bioinf.jku.at/contest_dataset#disease_maps_to_modelling_covid-19',
    'completed',
    'intermediate',
    '7',
    NULL,
    '2022-05-20'
  ),
  (
    '161',
    'crowdsourced-evaluation-of-inchi-based-tautomer-identification',
    'Crowdsourced Evaluation of InChI-based Tautomer Identification',
    'Calling on scientists from industry, government, and academia dealing with chemi',
    'This challenge focuses on the International Chemical Identifier (InChI), which was developed and is maintained under the auspices of the International Union of Pure and Applied Chemistry (IUPAC) and the InChI Trust. The InChI Trust, the IUPAC Working Group on Tautomers, and ...',
    'https://precision.fda.gov/challenges/29',
    'completed',
    'intermediate',
    '6',
    '2022-11-01',
    '2023-03-01'
  ),
  (
    '162',
    'nctr-indel-calling-from-oncopanel-sequencing-challenge-phase-2',
    'NCTR Indel Calling from Oncopanel Sequencing Challenge Phase 2',
    'In Phase 2, participants who completed in Phase 1 of the challenge have the opti',
    'The high value of clinically actionable information obtained by oncopanel sequencing makes it a crucial tool for precision oncology[1,2]. With the surge in availability of oncopanels, it is critical to ensure that they have been thoroughly tested and are properly used. FDA h...',
    'https://precision.fda.gov/challenges/22',
    'completed',
    'intermediate',
    '6',
    '2022-07-11',
    '2022-07-26'
  ),
  (
    '163',
    'nctr-indel-calling-from-oncopanel-sequencing-data-challenge-phase-1',
    'NCTR Indel Calling from Oncopanel Sequencing Data Challenge Phase 1',
    'Genetic variation involving indels (insertions and deletions) in the cancer geno',
    'The high value of clinically actionable information obtained by oncopanel sequencing makes it a crucial tool for precision oncology[1,2]. With the surge in availability of oncopanels, it is critical to ensure that they have been thoroughly tested and are properly used. FDA h...',
    'https://precision.fda.gov/challenges/21',
    'completed',
    'intermediate',
    '6',
    '2022-05-02',
    '2022-07-08'
  ),
  (
    '164',
    'vha-innovation-ecosystem-and-precisionfda-covid-19-risk-factor-modeling-challenge-phase-2',
    'VHA Innovation Ecosystem and precisionFDA COVID-19 Risk Factor Modeling Challenge Phase 2',
    'The focus of Phase 2 was to validate the top performing models on two additional',
    'The novel coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2,” or SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandem...',
    'https://precision.fda.gov/challenges/20',
    'completed',
    'intermediate',
    '6',
    '2021-04-14',
    '2022-01-28'
  ),
  (
    '165',
    'tumor-mutational-burden-tmb-challenge-phase-2',
    'Tumor Mutational Burden (TMB) Challenge Phase 2',
    'The goal of the Friends of Cancer Research and precisionFDA Tumor Mutational Bur',
    'Tumor mutational burden (TMB) is generally defined as the number of mutations detected in a patient’s tumor sample per megabase of DNA sequenced. However different algorithms use different methods for calculating TMB. Mutations in genes in tumor cells may lead to the creatio...',
    'https://precision.fda.gov/challenges/18',
    'completed',
    'intermediate',
    '6',
    '2021-07-19',
    '2021-09-12'
  ),
  (
    '166',
    'predicting-gene-expression-using-millions-of-random-promoter-sequences',
    'Predicting Gene Expression Using Millions of Random Promoter Sequences',
    '',
    'Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in a process termed “cis-regulatory logic”, where proteins called Transcription Factors (TFs) bind to specific DNA sequences within the genome and work toget...',
    'https://www.synapse.org/#!Synapse:syn28469146/wiki/617075',
    'completed',
    'intermediate',
    '1',
    '2022-06-15',
    '2022-08-07'
  );

  -- challenge_organization_role data

INSERT INTO challenge_contribution (id, challenge_id, organization_id, role)
VALUES ('1', 1, 75, 'sponsor'),
  ('2', 2, 28, 'data_contributor'),
  ('3', 2, 45, 'data_contributor'),
  ('4', 2, 151, 'data_contributor'),
  ('5', 2, 52, 'sponsor'),
  ('6', 3, 154, 'data_contributor'),
  ('7', 3, 118, 'data_contributor'),
  ('8', 3, 17, 'data_contributor'),
  ('9', 3, 142, 'data_contributor'),
  ('10', 4, 150, 'data_contributor'),
  ('11', 4, 52, 'data_contributor'),
  ('12', 4, 131, 'sponsor'),
  ('13', 5, 101, 'data_contributor'),
  ('14', 6, 54, 'challenge_organizer'),
  ('15', 6, 146, 'challenge_organizer'),
  ('16', 6, 171, 'challenge_organizer'),
  ('17', 6, 227, 'challenge_organizer'),
  ('18', 6, 27, 'challenge_organizer'),
  ('19', 6, 128, 'challenge_organizer'),
  ('20', 6, 93, 'challenge_organizer'),
  ('21', 6, 179, 'challenge_organizer'),
  ('22', 6, 89, 'challenge_organizer'),
  ('23', 6, 73, 'challenge_organizer'),
  ('24', 6, 170, 'challenge_organizer'),
  ('25', 6, 119, 'challenge_organizer'),
  ('26', 6, 171, 'sponsor'),
  ('27', 6, 93, 'sponsor'),
  ('28', 6, 57, 'sponsor'),
  ('29', 6, 146, 'sponsor'),
  ('30', 6, 120, 'sponsor'),
  ('31', 7, 171, 'challenge_organizer'),
  ('32', 7, 128, 'challenge_organizer'),
  ('33', 7, 93, 'challenge_organizer'),
  ('34', 7, 71, 'challenge_organizer'),
  ('35', 7, 89, 'challenge_organizer'),
  ('36', 7, 73, 'challenge_organizer'),
  ('37', 7, 170, 'challenge_organizer'),
  ('38', 7, 150, 'challenge_organizer'),
  ('39', 7, 130, 'challenge_organizer'),
  ('40', 8, 171, 'challenge_organizer'),
  ('41', 8, 206, 'challenge_organizer'),
  ('42', 8, 128, 'challenge_organizer'),
  ('43', 8, 93, 'challenge_organizer'),
  ('44', 8, 56, 'challenge_organizer'),
  ('45', 8, 37, 'challenge_organizer'),
  ('46', 8, 25, 'challenge_organizer'),
  ('47', 8, 78, 'challenge_organizer'),
  ('48', 8, 125, 'challenge_organizer'),
  ('49', 8, 23, 'challenge_organizer'),
  ('50', 8, 55, 'data_contributor'),
  ('51', 8, 24, 'sponsor'),
  ('52', 8, 125, 'sponsor'),
  ('53', 8, 145, 'sponsor'),
  ('54', 8, 181, 'sponsor'),
  ('55', 8, 93, 'sponsor'),
  ('56', 9, 171, 'challenge_organizer'),
  ('57', 9, 150, 'challenge_organizer'),
  ('58', 9, 128, 'challenge_organizer'),
  ('59', 9, 93, 'challenge_organizer'),
  ('60', 9, 197, 'challenge_organizer'),
  ('61', 9, 149, 'challenge_organizer'),
  ('62', 9, 23, 'challenge_organizer'),
  ('63', 9, 99, 'data_contributor'),
  ('64', 10, 165, 'challenge_organizer'),
  ('65', 10, 171, 'challenge_organizer'),
  ('66', 10, 128, 'challenge_organizer'),
  ('67', 10, 93, 'challenge_organizer'),
  ('68', 10, 23, 'challenge_organizer'),
  ('69', 10, 122, 'challenge_organizer'),
  ('70', 10, 122, 'data_contributor'),
  ('71', 10, 122, 'sponsor'),
  ('72', 10, 93, 'sponsor'),
  ('73', 10, 171, 'sponsor'),
  ('74', 10, 165, 'sponsor'),
  ('75', 11, 171, 'challenge_organizer'),
  ('76', 11, 150, 'challenge_organizer'),
  ('77', 11, 128, 'challenge_organizer'),
  ('78', 11, 41, 'challenge_organizer'),
  ('79', 11, 58, 'challenge_organizer'),
  ('80', 11, 205, 'challenge_organizer'),
  ('81', 11, 93, 'challenge_organizer'),
  ('82', 11, 23, 'challenge_organizer'),
  ('83', 11, 41, 'data_contributor'),
  ('84', 11, 58, 'data_contributor'),
  ('85', 11, 46, 'sponsor'),
  ('86', 11, 109, 'sponsor'),
  ('87', 12, 107, 'challenge_organizer'),
  ('88', 12, 171, 'challenge_organizer'),
  ('89', 12, 204, 'challenge_organizer'),
  ('90', 12, 128, 'challenge_organizer'),
  ('91', 12, 93, 'challenge_organizer'),
  ('92', 12, 38, 'challenge_organizer'),
  ('93', 12, 223, 'challenge_organizer'),
  ('94', 12, 119, 'challenge_organizer'),
  ('95', 12, 23, 'challenge_organizer'),
  ('96', 12, 82, 'challenge_organizer'),
  ('97', 12, 169, 'data_contributor'),
  ('98', 12, 18, 'data_contributor'),
  ('99', 12, 94, 'data_contributor'),
  ('100', 12, 19, 'sponsor'),
  ('101', 12, 39, 'sponsor'),
  ('102', 12, 74, 'sponsor'),
  ('103', 12, 153, 'sponsor'),
  ('104', 12, 164, 'sponsor'),
  ('105', 12, 168, 'sponsor'),
  ('106', 12, 172, 'sponsor'),
  ('107', 12, 181, 'sponsor'),
  ('108', 13, 206, 'challenge_organizer'),
  ('109', 13, 167, 'challenge_organizer'),
  ('110', 13, 171, 'challenge_organizer'),
  ('111', 13, 93, 'challenge_organizer'),
  ('112', 13, 128, 'challenge_organizer'),
  ('113', 13, 23, 'challenge_organizer'),
  ('114', 13, 167, 'data_contributor'),
  ('115', 13, 100, 'sponsor'),
  ('116', 13, 93, 'sponsor'),
  ('117', 13, 171, 'sponsor'),
  ('118', 13, 1, 'sponsor'),
  ('119', 14, 58, 'challenge_organizer'),
  ('120', 14, 93, 'challenge_organizer'),
  ('121', 14, 124, 'challenge_organizer'),
  ('122', 14, 155, 'challenge_organizer'),
  ('123', 14, 157, 'challenge_organizer'),
  ('124', 14, 171, 'challenge_organizer'),
  ('125', 14, 188, 'challenge_organizer'),
  ('126', 14, 196, 'challenge_organizer'),
  ('127', 14, 199, 'challenge_organizer'),
  ('128', 14, 219, 'challenge_organizer'),
  ('129', 14, 26, 'data_contributor'),
  ('130', 14, 47, 'data_contributor'),
  ('131', 14, 172, 'data_contributor'),
  ('132', 14, 124, 'data_contributor'),
  ('133', 14, 157, 'sponsor'),
  ('134', 14, 131, 'sponsor'),
  ('135', 14, 21, 'sponsor'),
  ('136', 15, 128, 'challenge_organizer'),
  ('137', 15, 93, 'challenge_organizer'),
  ('138', 15, 171, 'challenge_organizer'),
  ('139', 15, 118, 'challenge_organizer'),
  ('140', 15, 154, 'challenge_organizer'),
  ('141', 15, 187, 'challenge_organizer'),
  ('142', 15, 115, 'challenge_organizer'),
  ('143', 15, 23, 'challenge_organizer'),
  ('144', 15, 154, 'data_contributor'),
  ('145', 15, 140, 'data_contributor'),
  ('146', 15, 142, 'data_contributor'),
  ('147', 15, 154, 'sponsor'),
  ('148', 15, 93, 'sponsor'),
  ('149', 15, 171, 'sponsor'),
  ('150', 15, 1, 'sponsor'),
  ('151', 15, 32, 'sponsor'),
  ('152', 15, 67, 'sponsor'),
  ('153', 16, 128, 'challenge_organizer'),
  ('154', 16, 93, 'challenge_organizer'),
  ('155', 16, 26, 'challenge_organizer'),
  ('156', 16, 89, 'challenge_organizer'),
  ('157', 16, 73, 'challenge_organizer'),
  ('158', 16, 170, 'challenge_organizer'),
  ('159', 16, 171, 'challenge_organizer'),
  ('160', 16, 23, 'challenge_organizer'),
  ('161', 16, 26, 'data_contributor'),
  ('162', 16, 235, 'data_contributor'),
  ('163', 16, 29, 'data_contributor'),
  ('164', 16, 26, 'sponsor'),
  ('165', 17, 128, 'challenge_organizer'),
  ('166', 17, 93, 'challenge_organizer'),
  ('167', 17, 197, 'challenge_organizer'),
  ('168', 17, 149, 'challenge_organizer'),
  ('169', 17, 171, 'challenge_organizer'),
  ('170', 17, 23, 'challenge_organizer'),
  ('171', 17, 99, 'data_contributor'),
  ('172', 17, 149, 'sponsor'),
  ('173', 17, 81, 'sponsor'),
  ('174', 17, 138, 'sponsor'),
  ('175', 17, 171, 'sponsor'),
  ('176', 17, 197, 'sponsor'),
  ('177', 17, 150, 'sponsor'),
  ('178', 18, 235, 'challenge_organizer'),
  ('179', 18, 128, 'challenge_organizer'),
  ('180', 18, 93, 'challenge_organizer'),
  ('181', 18, 197, 'challenge_organizer'),
  ('182', 18, 150, 'challenge_organizer'),
  ('183', 18, 149, 'challenge_organizer'),
  ('184', 18, 79, 'challenge_organizer'),
  ('185', 18, 220, 'challenge_organizer'),
  ('186', 18, 171, 'challenge_organizer'),
  ('187', 18, 23, 'challenge_organizer'),
  ('188', 18, 149, 'data_contributor'),
  ('189', 18, 99, 'data_contributor'),
  ('190', 18, 149, 'data_contributor'),
  ('191', 18, 156, 'sponsor'),
  ('192', 18, 81, 'sponsor'),
  ('193', 18, 138, 'sponsor'),
  ('194', 19, 171, 'challenge_organizer'),
  ('195', 19, 64, 'challenge_organizer'),
  ('196', 19, 229, 'challenge_organizer'),
  ('197', 19, 59, 'challenge_organizer'),
  ('198', 19, 59, 'sponsor'),
  ('199', 20, 171, 'challenge_organizer'),
  ('200', 20, 205, 'challenge_organizer'),
  ('201', 20, 128, 'challenge_organizer'),
  ('202', 20, 93, 'challenge_organizer'),
  ('203', 20, 89, 'challenge_organizer'),
  ('204', 20, 73, 'challenge_organizer'),
  ('205', 20, 170, 'challenge_organizer'),
  ('206', 20, 118, 'challenge_organizer'),
  ('207', 20, 23, 'challenge_organizer'),
  ('208', 20, 111, 'challenge_organizer'),
  ('209', 20, 205, 'data_contributor'),
  ('210', 20, 180, 'sponsor'),
  ('211', 21, 179, 'challenge_organizer'),
  ('212', 21, 171, 'challenge_organizer'),
  ('213', 21, 128, 'challenge_organizer'),
  ('214', 21, 93, 'challenge_organizer'),
  ('215', 21, 199, 'challenge_organizer'),
  ('216', 21, 150, 'challenge_organizer'),
  ('217', 21, 115, 'challenge_organizer'),
  ('218', 21, 23, 'challenge_organizer'),
  ('219', 21, 69, 'data_contributor'),
  ('220', 22, 220, 'challenge_organizer'),
  ('221', 22, 91, 'challenge_organizer'),
  ('222', 22, 127, 'challenge_organizer'),
  ('223', 22, 95, 'challenge_organizer'),
  ('224', 22, 128, 'challenge_organizer'),
  ('225', 22, 93, 'challenge_organizer'),
  ('226', 22, 171, 'challenge_organizer'),
  ('227', 22, 23, 'challenge_organizer'),
  ('228', 22, 64, 'data_contributor'),
  ('229', 22, 229, 'data_contributor'),
  ('230', 23, 232, 'challenge_organizer'),
  ('231', 23, 128, 'challenge_organizer'),
  ('232', 23, 93, 'challenge_organizer'),
  ('233', 23, 197, 'challenge_organizer'),
  ('234', 23, 150, 'challenge_organizer'),
  ('235', 23, 149, 'challenge_organizer'),
  ('236', 23, 171, 'challenge_organizer'),
  ('237', 23, 23, 'challenge_organizer'),
  ('238', 23, 99, 'data_contributor'),
  ('239', 23, 131, 'data_contributor'),
  ('240', 23, 149, 'data_contributor'),
  ('241', 23, 138, 'sponsor'),
  ('242', 23, 81, 'sponsor'),
  ('243', 23, 156, 'sponsor'),
  ('244', 23, 131, 'sponsor'),
  ('245', 24, 171, 'challenge_organizer'),
  ('246', 24, 93, 'challenge_organizer'),
  ('247', 24, 106, 'challenge_organizer'),
  ('248', 24, 128, 'challenge_organizer'),
  ('249', 24, 175, 'challenge_organizer'),
  ('250', 24, 189, 'challenge_organizer'),
  ('251', 24, 36, 'data_contributor'),
  ('252', 24, 128, 'data_contributor'),
  ('253', 24, 110, 'sponsor'),
  ('254', 24, 80, 'sponsor'),
  ('255', 24, 236, 'sponsor'),
  ('256', 24, 93, 'sponsor'),
  ('257', 24, 20, 'sponsor'),
  ('258', 25, 47, 'challenge_organizer'),
  ('259', 25, 129, 'challenge_organizer'),
  ('260', 25, 171, 'challenge_organizer'),
  ('261', 25, 193, 'data_contributor'),
  ('262', 25, 58, 'data_contributor'),
  ('263', 25, 86, 'data_contributor'),
  ('264', 25, 89, 'data_contributor'),
  ('265', 25, 129, 'data_contributor'),
  ('266', 25, 47, 'sponsor'),
  ('267', 26, 85, 'challenge_organizer'),
  ('268', 26, 197, 'challenge_organizer'),
  ('269', 26, 63, 'challenge_organizer'),
  ('270', 26, 149, 'challenge_organizer'),
  ('271', 26, 171, 'challenge_organizer'),
  ('272', 26, 131, 'data_contributor'),
  ('273', 26, 88, 'data_contributor'),
  ('274', 26, 179, 'data_contributor'),
  ('275', 26, 49, 'data_contributor'),
  ('276', 26, 108, 'data_contributor'),
  ('277', 26, 202, 'data_contributor'),
  ('278', 26, 197, 'data_contributor'),
  ('279', 26, 149, 'data_contributor'),
  ('280', 26, 99, 'data_contributor'),
  ('281', 26, 41, 'data_contributor'),
  ('282', 27, 126, 'challenge_organizer'),
  ('283', 27, 65, 'challenge_organizer'),
  ('284', 27, 230, 'challenge_organizer'),
  ('285', 27, 88, 'challenge_organizer'),
  ('286', 27, 171, 'challenge_organizer'),
  ('287', 27, 224, 'challenge_organizer'),
  ('288', 27, 208, 'challenge_organizer'),
  ('289', 27, 216, 'challenge_organizer'),
  ('290', 27, 126, 'data_contributor'),
  ('291', 27, 171, 'data_contributor'),
  ('292', 27, 126, 'sponsor'),
  ('293', 27, 166, 'sponsor'),
  ('294', 28, 141, 'challenge_organizer'),
  ('295', 28, 128, 'challenge_organizer'),
  ('296', 28, 93, 'challenge_organizer'),
  ('297', 28, 131, 'challenge_organizer'),
  ('298', 28, 89, 'challenge_organizer'),
  ('299', 28, 73, 'challenge_organizer'),
  ('300', 28, 170, 'challenge_organizer'),
  ('301', 28, 149, 'challenge_organizer'),
  ('302', 28, 59, 'challenge_organizer'),
  ('303', 28, 152, 'challenge_organizer'),
  ('304', 28, 171, 'challenge_organizer'),
  ('305', 28, 51, 'data_contributor'),
  ('306', 28, 51, 'sponsor'),
  ('307', 28, 59, 'sponsor'),
  ('308', 28, 147, 'sponsor'),
  ('309', 29, 211, 'challenge_organizer'),
  ('310', 29, 128, 'challenge_organizer'),
  ('311', 29, 210, 'challenge_organizer'),
  ('312', 29, 171, 'challenge_organizer'),
  ('313', 29, 195, 'challenge_organizer'),
  ('314', 29, 128, 'data_contributor'),
  ('315', 29, 128, 'sponsor'),
  ('316', 30, 89, 'challenge_organizer'),
  ('317', 30, 128, 'challenge_organizer'),
  ('318', 30, 93, 'challenge_organizer'),
  ('319', 30, 73, 'challenge_organizer'),
  ('320', 30, 170, 'challenge_organizer'),
  ('321', 30, 121, 'challenge_organizer'),
  ('322', 30, 171, 'challenge_organizer'),
  ('323', 30, 121, 'data_contributor'),
  ('324', 31, 171, 'challenge_organizer'),
  ('325', 31, 96, 'challenge_organizer'),
  ('326', 31, 128, 'challenge_organizer'),
  ('327', 31, 93, 'challenge_organizer'),
  ('328', 31, 190, 'data_contributor'),
  ('329', 31, 15, 'sponsor'),
  ('330', 32, 87, 'challenge_organizer'),
  ('331', 32, 48, 'challenge_organizer'),
  ('332', 32, 66, 'challenge_organizer'),
  ('333', 32, 128, 'challenge_organizer'),
  ('334', 32, 93, 'challenge_organizer'),
  ('335', 32, 171, 'challenge_organizer'),
  ('336', 32, 182, 'data_contributor'),
  ('337', 32, 116, 'data_contributor'),
  ('338', 32, 15, 'data_contributor'),
  ('339', 32, 31, 'sponsor'),
  ('340', 33, 233, 'challenge_organizer'),
  ('341', 33, 196, 'challenge_organizer'),
  ('342', 33, 128, 'challenge_organizer'),
  ('343', 33, 93, 'challenge_organizer'),
  ('344', 33, 199, 'challenge_organizer'),
  ('345', 33, 179, 'challenge_organizer'),
  ('346', 33, 72, 'challenge_organizer'),
  ('347', 33, 72, 'data_contributor'),
  ('348', 33, 233, 'data_contributor'),
  ('349', 33, 117, 'data_contributor'),
  ('350', 34, 89, 'challenge_organizer'),
  ('351', 34, 226, 'challenge_organizer'),
  ('352', 34, 171, 'challenge_organizer'),
  ('353', 34, 73, 'challenge_organizer'),
  ('354', 34, 170, 'challenge_organizer'),
  ('355', 34, 71, 'challenge_organizer'),
  ('356', 34, 226, 'data_contributor'),
  ('357', 34, 71, 'data_contributor'),
  ('358', 35, 171, 'challenge_organizer'),
  ('359', 35, 224, 'challenge_organizer'),
  ('360', 35, 224, 'data_contributor'),
  ('361', 35, 133, 'sponsor'),
  ('362', 35, 97, 'sponsor'),
  ('363', 35, 224, 'sponsor'),
  ('364', 36, 43, 'challenge_organizer'),
  ('365', 36, 171, 'challenge_organizer'),
  ('366', 36, 234, 'challenge_organizer'),
  ('367', 36, 114, 'challenge_organizer'),
  ('368', 36, 224, 'challenge_organizer'),
  ('369', 36, 16, 'challenge_organizer'),
  ('370', 36, 93, 'challenge_organizer'),
  ('371', 36, 43, 'data_contributor'),
  ('372', 36, 114, 'data_contributor'),
  ('373', 36, 234, 'data_contributor'),
  ('374', 37, 95, 'challenge_organizer'),
  ('375', 37, 113, 'challenge_organizer'),
  ('376', 37, 150, 'challenge_organizer'),
  ('377', 37, 171, 'challenge_organizer'),
  ('378', 37, 179, 'challenge_organizer'),
  ('379', 37, 16, 'data_contributor'),
  ('380', 37, 234, 'data_contributor'),
  ('381', 37, 114, 'data_contributor'),
  ('382', 37, 43, 'data_contributor'),
  ('383', 37, 171, 'data_contributor'),
  ('384', 37, 131, 'sponsor'),
  ('385', 38, 171, 'challenge_organizer'),
  ('386', 38, 52, 'challenge_organizer'),
  ('387', 38, 176, 'challenge_organizer'),
  ('388', 38, 15, 'challenge_organizer'),
  ('389', 38, 131, 'challenge_organizer'),
  ('390', 38, 46, 'challenge_organizer'),
  ('391', 38, 128, 'challenge_organizer'),
  ('392', 38, 93, 'challenge_organizer'),
  ('393', 38, 89, 'challenge_organizer'),
  ('394', 38, 73, 'challenge_organizer'),
  ('395', 38, 170, 'challenge_organizer'),
  ('396', 38, 52, 'data_contributor'),
  ('397', 39, 171, 'challenge_organizer'),
  ('398', 39, 150, 'challenge_organizer'),
  ('399', 39, 128, 'challenge_organizer'),
  ('400', 39, 15, 'challenge_organizer'),
  ('401', 39, 131, 'challenge_organizer'),
  ('402', 39, 46, 'challenge_organizer'),
  ('403', 39, 112, 'data_contributor'),
  ('404', 39, 150, 'data_contributor'),
  ('405', 40, 131, 'challenge_organizer'),
  ('406', 40, 171, 'challenge_organizer'),
  ('407', 40, 150, 'challenge_organizer'),
  ('408', 40, 22, 'data_contributor'),
  ('409', 40, 44, 'data_contributor'),
  ('410', 40, 131, 'sponsor'),
  ('411', 41, 192, 'challenge_organizer'),
  ('412', 41, 128, 'challenge_organizer'),
  ('413', 41, 93, 'challenge_organizer'),
  ('414', 41, 199, 'challenge_organizer'),
  ('415', 41, 171, 'challenge_organizer'),
  ('416', 41, 192, 'data_contributor'),
  ('417', 41, 133, 'sponsor'),
  ('418', 41, 40, 'sponsor'),
  ('419', 42, 171, 'challenge_organizer'),
  ('420', 42, 144, 'challenge_organizer'),
  ('421', 42, 126, 'challenge_organizer'),
  ('422', 42, 76, 'challenge_organizer'),
  ('423', 42, 126, 'data_contributor'),
  ('424', 42, 144, 'data_contributor'),
  ('425', 42, 216, 'data_contributor'),
  ('426', 42, 191, 'data_contributor'),
  ('427', 42, 198, 'data_contributor'),
  ('428', 42, 161, 'data_contributor'),
  ('429', 43, 171, 'challenge_organizer'),
  ('430', 43, 52, 'challenge_organizer'),
  ('431', 43, 176, 'challenge_organizer'),
  ('432', 43, 15, 'challenge_organizer'),
  ('433', 43, 46, 'challenge_organizer'),
  ('434', 43, 128, 'challenge_organizer'),
  ('435', 43, 89, 'challenge_organizer'),
  ('436', 43, 52, 'data_contributor'),
  ('437', 43, 46, 'sponsor'),
  ('438', 44, 171, 'challenge_organizer'),
  ('439', 44, 224, 'challenge_organizer'),
  ('440', 44, 224, 'data_contributor'),
  ('441', 45, 211, 'challenge_organizer'),
  ('442', 45, 40, 'challenge_organizer'),
  ('443', 45, 148, 'challenge_organizer'),
  ('444', 45, 171, 'challenge_organizer'),
  ('445', 45, 40, 'data_contributor'),
  ('446', 46, 215, 'challenge_organizer'),
  ('447', 46, 131, 'challenge_organizer'),
  ('448', 46, 196, 'data_contributor'),
  ('449', 46, 220, 'data_contributor'),
  ('450', 46, 171, 'challenge_organizer'),
  ('451', 46, 185, 'data_contributor'),
  ('452', 46, 61, 'data_contributor'),
  ('453', 46, 226, 'challenge_organizer'),
  ('454', 46, 148, 'data_contributor'),
  ('455', 47, 47, 'challenge_organizer'),
  ('456', 47, 171, 'challenge_organizer'),
  ('457', 47, 47, 'sponsor'),
  ('458', 59, 30, 'data_contributor'),
  ('459', 59, 224, 'data_contributor'),
  ('460', 59, 196, 'data_contributor'),
  ('461', 61, 64, 'data_contributor'),
  ('462', 62, 173, 'data_contributor'),
  ('463', 63, 224, 'data_contributor'),
  ('464', 64, 184, 'data_contributor'),
  ('465', 65, 33, 'data_contributor'),
  ('466', 66, 196, 'data_contributor'),
  ('467', 67, 159, 'data_contributor'),
  ('468', 67, 70, 'data_contributor'),
  ('469', 68, 42, 'data_contributor'),
  ('470', 69, 200, 'data_contributor'),
  ('471', 70, 91, 'data_contributor'),
  ('472', 71, 214, 'data_contributor'),
  ('473', 72, 179, 'data_contributor'),
  ('474', 73, 41, 'data_contributor'),
  ('475', 74, 213, 'data_contributor'),
  ('476', 75, 91, 'data_contributor'),
  ('477', 76, 88, 'data_contributor'),
  ('478', 77, 220, 'data_contributor'),
  ('479', 78, 222, 'data_contributor'),
  ('480', 79, 217, 'data_contributor'),
  ('481', 80, 221, 'data_contributor'),
  ('482', 81, 173, 'data_contributor'),
  ('483', 82, 173, 'data_contributor'),
  ('484', 83, 220, 'data_contributor'),
  ('485', 84, 218, 'data_contributor'),
  ('486', 85, 41, 'data_contributor'),
  ('487', 90, 104, 'challenge_organizer'),
  ('488', 90, 3, 'challenge_organizer'),
  ('489', 90, 102, 'challenge_organizer'),
  ('490', 90, 215, 'challenge_organizer'),
  ('491', 90, 143, 'challenge_organizer'),
  ('492', 90, 224, 'challenge_organizer'),
  ('493', 90, 203, 'challenge_organizer'),
  ('494', 90, 219, 'challenge_organizer'),
  ('495', 90, 137, 'sponsor'),
  ('496', 90, 15, 'sponsor'),
  ('497', 90, 60, 'sponsor'),
  ('498', 90, 68, 'sponsor'),
  ('499', 91, 209, 'challenge_organizer'),
  ('500', 91, 183, 'challenge_organizer'),
  ('501', 91, 194, 'challenge_organizer'),
  ('502', 91, 207, 'challenge_organizer'),
  ('503', 91, 135, 'sponsor'),
  ('504', 92, 209, 'challenge_organizer'),
  ('505', 92, 183, 'challenge_organizer'),
  ('506', 92, 194, 'challenge_organizer'),
  ('507', 92, 207, 'challenge_organizer'),
  ('508', 92, 135, 'sponsor'),
  ('509', 93, 189, 'sponsor'),
  ('510', 94, 13, 'challenge_organizer'),
  ('511', 94, 189, 'challenge_organizer'),
  ('512', 94, 34, 'challenge_organizer'),
  ('513', 94, 62, 'challenge_organizer'),
  ('514', 94, 228, 'challenge_organizer'),
  ('515', 94, 136, 'challenge_organizer'),
  ('516', 94, 189, 'sponsor'),
  ('517', 95, 13, 'challenge_organizer'),
  ('518', 95, 189, 'challenge_organizer'),
  ('519', 95, 152, 'challenge_organizer'),
  ('520', 95, 201, 'challenge_organizer'),
  ('521', 95, 128, 'challenge_organizer'),
  ('522', 95, 93, 'challenge_organizer'),
  ('523', 95, 62, 'challenge_organizer'),
  ('524', 95, 34, 'challenge_organizer'),
  ('525', 95, 189, 'sponsor'),
  ('526', 96, 13, 'challenge_organizer'),
  ('527', 96, 189, 'challenge_organizer'),
  ('528', 96, 82, 'challenge_organizer'),
  ('529', 96, 62, 'challenge_organizer'),
  ('530', 96, 34, 'challenge_organizer'),
  ('531', 96, 189, 'sponsor'),
  ('532', 97, 13, 'challenge_organizer'),
  ('533', 97, 189, 'challenge_organizer'),
  ('534', 97, 83, 'challenge_organizer'),
  ('535', 97, 34, 'challenge_organizer'),
  ('536', 97, 189, 'sponsor'),
  ('537', 98, 13, 'challenge_organizer'),
  ('538', 98, 189, 'challenge_organizer'),
  ('539', 98, 62, 'challenge_organizer'),
  ('540', 98, 53, 'challenge_organizer'),
  ('541', 98, 34, 'challenge_organizer'),
  ('542', 98, 189, 'sponsor'),
  ('543', 99, 136, 'challenge_organizer'),
  ('544', 99, 13, 'challenge_organizer'),
  ('545', 99, 189, 'challenge_organizer'),
  ('546', 99, 62, 'challenge_organizer'),
  ('547', 99, 34, 'challenge_organizer'),
  ('548', 99, 189, 'sponsor'),
  ('549', 100, 13, 'challenge_organizer'),
  ('550', 100, 189, 'challenge_organizer'),
  ('551', 100, 231, 'challenge_organizer'),
  ('552', 100, 34, 'challenge_organizer'),
  ('553', 100, 62, 'challenge_organizer'),
  ('554', 100, 189, 'sponsor'),
  ('555', 101, 13, 'challenge_organizer'),
  ('556', 101, 189, 'challenge_organizer'),
  ('557', 101, 34, 'challenge_organizer'),
  ('558', 101, 62, 'challenge_organizer'),
  ('559', 101, 189, 'sponsor'),
  ('560', 102, 13, 'challenge_organizer'),
  ('561', 102, 189, 'challenge_organizer'),
  ('562', 102, 34, 'challenge_organizer'),
  ('563', 102, 62, 'challenge_organizer'),
  ('564', 102, 189, 'sponsor'),
  ('565', 103, 13, 'challenge_organizer'),
  ('566', 103, 189, 'challenge_organizer'),
  ('567', 103, 34, 'challenge_organizer'),
  ('568', 103, 62, 'challenge_organizer'),
  ('569', 103, 131, 'challenge_organizer'),
  ('570', 103, 177, 'challenge_organizer'),
  ('571', 103, 189, 'sponsor'),
  ('572', 104, 12, 'challenge_organizer'),
  ('573', 104, 215, 'challenge_organizer'),
  ('574', 104, 84, 'challenge_organizer'),
  ('575', 104, 7, 'challenge_organizer'),
  ('576', 104, 15, 'sponsor'),
  ('577', 104, 90, 'sponsor'),
  ('578', 104, 103, 'sponsor'),
  ('579', 104, 50, 'sponsor'),
  ('580', 105, 12, 'challenge_organizer'),
  ('581', 105, 147, 'sponsor'),
  ('582', 105, 35, 'sponsor'),
  ('583', 106, 12, 'challenge_organizer'),
  ('584', 106, 186, 'sponsor'),
  ('585', 106, 178, 'sponsor'),
  ('586', 107, 12, 'challenge_organizer'),
  ('587', 107, 77, 'sponsor'),
  ('588', 124, 12, 'challenge_organizer'),
  ('589', 124, 215, 'challenge_organizer'),
  ('590', 124, 84, 'challenge_organizer'),
  ('591', 124, 7, 'challenge_organizer'),
  ('592', 124, 98, 'sponsor'),
  ('593', 124, 139, 'sponsor'),
  ('594', 124, 162, 'sponsor'),
  ('595', 161, 13, 'challenge_organizer'),
  ('596', 161, 237, 'challenge_organizer'),
  ('597', 162, 13, 'challenge_organizer'),
  ('598', 162, 238, 'challenge_organizer'),
  ('599', 163, 13, 'challenge_organizer'),
  ('600', 163, 238, 'challenge_organizer'),
  ('601', 164, 13, 'challenge_organizer'),
  ('602', 164, 231, 'challenge_organizer'),
  ('603', 165, 13, 'sponsor'),
  ('604', 55, 1, 'sponsor'),
  ('605', 53, 1, 'sponsor'),
  ('606', 52, 1, 'sponsor'),
  ('607', 54, 1, 'sponsor'),
  ('608', 166, 1, 'sponsor'),
  ('609', 45, 1, 'sponsor'),
  ('610', 44, 1, 'sponsor'),
  ('611', 43, 1, 'sponsor'),
  ('612', 40, 1, 'sponsor'),
  ('613', 42, 1, 'sponsor'),
  ('614', 39, 1, 'sponsor'),
  ('615', 41, 1, 'sponsor'),
  ('616', 35, 1, 'sponsor'),
  ('617', 36, 1, 'sponsor'),
  ('618', 34, 1, 'sponsor'),
  ('619', 37, 1, 'sponsor'),
  ('620', 33, 1, 'sponsor'),
  ('621', 32, 1, 'sponsor'),
  ('622', 31, 1, 'sponsor'),
  ('623', 30, 1, 'sponsor'),
  ('624', 29, 1, 'sponsor'),
  ('625', 21, 1, 'sponsor'),
  ('626', 27, 1, 'sponsor'),
  ('627', 26, 1, 'sponsor'),
  ('628', 28, 1, 'sponsor'),
  ('629', 24, 1, 'sponsor'),
  ('630', 25, 1, 'sponsor'),
  ('631', 23, 1, 'sponsor'),
  ('632', 20, 1, 'sponsor'),
  ('633', 19, 1, 'sponsor'),
  ('634', 18, 1, 'sponsor'),
  ('635', 17, 1, 'sponsor'),
  ('636', 16, 1, 'sponsor'),
  ('637', 15, 1, 'sponsor'),
  ('638', 14, 1, 'sponsor'),
  ('639', 8, 1, 'sponsor'),
  ('640', 13, 1, 'sponsor'),
  ('641', 7, 1, 'sponsor'),
  ('642', 11, 1, 'sponsor'),
  ('643', 12, 1, 'sponsor'),
  ('644', 10, 1, 'sponsor'),
  ('645', 9, 1, 'sponsor'),
  ('646', 6, 1, 'sponsor'),
  ('647', 7, 1, 'sponsor'),
  ('648', 5, 1, 'sponsor'),
  ('649', 4, 1, 'sponsor'),
  ('650', 1, 1, 'sponsor'),
  ('651', 3, 1, 'sponsor');

-- challenge_incentive data

INSERT INTO challenge_incentive (id, name, challenge_id)
VALUES ('1', 'publication', 1),
  ('2', 'publication', 2),
  ('3', 'speaking_engagement', 2),
  ('4', 'monetary', 3),
  ('5', 'publication', 5),
  ('6', 'speaking_engagement', 5),
  ('7', 'publication', 6),
  ('8', 'speaking_engagement', 6),
  ('9', 'monetary', 7),
  ('10', 'publication', 7),
  ('11', 'publication', 8),
  ('12', 'speaking_engagement', 8),
  ('13', 'publication', 9),
  ('14', 'publication', 10),
  ('15', 'speaking_engagement', 10),
  ('16', 'publication', 11),
  ('17', 'speaking_engagement', 11),
  ('18', 'publication', 12),
  ('19', 'speaking_engagement', 12),
  ('20', 'monetary', 14),
  ('21', 'publication', 14),
  ('22', 'speaking_engagement', 14),
  ('23', 'monetary', 15),
  ('24', 'publication', 15),
  ('25', 'speaking_engagement', 15),
  ('26', 'publication', 16),
  ('27', 'speaking_engagement', 16),
  ('28', 'publication', 17),
  ('29', 'speaking_engagement', 17),
  ('30', 'monetary', 24),
  ('31', 'publication', 24),
  ('32', 'speaking_engagement', 24),
  ('33', 'monetary', 25),
  ('34', 'publication', 25),
  ('35', 'speaking_engagement', 25),
  ('36', 'publication', 26),
  ('37', 'monetary', 27),
  ('38', 'publication', 27),
  ('39', 'publication', 28),
  ('40', 'publication', 29),
  ('41', 'publication', 30),
  ('42', 'publication', 31),
  ('43', 'speaking_engagement', 31),
  ('44', 'publication', 34),
  ('45', 'speaking_engagement', 34),
  ('46', 'publication', 37),
  ('47', 'speaking_engagement', 37),
  ('48', 'publication', 38),
  ('49', 'speaking_engagement', 38),
  ('50', 'publication', 100),
  ('51', 'speaking_engagement', 100),
  ('52', 'publication', 101),
  ('53', 'speaking_engagement', 101),
  ('54', 'monetary', 111),
  ('55', 'monetary', 113),
  ('56', 'monetary', 114),
  ('57', 'monetary', 118),
  ('58', 'monetary', 123),
  ('59', 'monetary', 124),
  ('60', 'monetary', 129),
  ('61', 'monetary', 131),
  ('62', 'monetary', 145),
  ('63', 'monetary', 146),
  ('64', 'monetary', 147),
  ('65', 'monetary', 148),
  ('66', 'monetary', 149),
  ('67', 'monetary', 156),
  ('68', 'publication', 157),
  ('69', 'other', 157),
  ('70', 'publication', 158),
  ('71', 'speaking_engagement', 158),
  ('72', 'publication', 159),
  ('73', 'speaking_engagement', 159),
  ('74', 'publication', 160),
  ('75', 'speaking_engagement', 160),
  ('76', 'publication', 161),
  ('77', 'other', 161),
  ('78', 'publication', 162),
  ('79', 'speaking_engagement', 162),
  ('80', 'publication', 163),
  ('81', 'speaking_engagement', 163),
  ('82', 'publication', 165),
  ('83', 'speaking_engagement', 166),
  ('84', 'other', 166);

-- challenge_submission_type data

INSERT INTO challenge_submission_type (id, name, challenge_id)
VALUES ('1', 'prediction_file', 1),
  ('2', 'prediction_file', 2),
  ('3', 'prediction_file', 3),
  ('4', 'prediction_file', 4),
  ('5', 'prediction_file', 5),
  ('6', 'prediction_file', 6),
  ('7', 'prediction_file', 7),
  ('8', 'prediction_file', 8),
  ('9', 'prediction_file', 9),
  ('10', 'prediction_file', 10),
  ('11', 'prediction_file', 11),
  ('12', 'prediction_file', 12),
  ('13', 'prediction_file', 13),
  ('14', 'prediction_file', 14),
  ('15', 'prediction_file', 15),
  ('16', 'prediction_file', 16),
  ('17', 'prediction_file', 17),
  ('18', 'prediction_file', 18),
  ('19', 'prediction_file', 19),
  ('20', 'prediction_file', 20),
  ('21', 'prediction_file', 21),
  ('22', 'other', 22),
  ('23', 'prediction_file', 23),
  ('24', 'container_image', 24),
  ('25', 'container_image', 25),
  ('26', 'prediction_file', 26),
  ('27', 'prediction_file', 27),
  ('28', 'container_image', 28),
  ('29', 'prediction_file', 29),
  ('30', 'prediction_file', 30),
  ('31', 'prediction_file', 31),
  ('32', 'prediction_file', 32),
  ('33', 'prediction_file', 33),
  ('34', 'prediction_file', 34),
  ('35', 'container_image', 35),
  ('36', 'prediction_file', 36),
  ('37', 'container_image', 37),
  ('38', 'prediction_file', 38),
  ('39', 'container_image', 39),
  ('40', 'container_image', 40),
  ('41', 'container_image', 41),
  ('42', 'prediction_file', 42),
  ('43', 'prediction_file', 43),
  ('44', 'container_image', 44),
  ('45', 'container_image', 45),
  ('46', 'prediction_file', 46),
  ('47', 'container_image', 46),
  ('48', 'container_image', 47),
  ('49', 'other', 48),
  ('50', 'prediction_file', 49),
  ('51', 'container_image', 49),
  ('52', 'prediction_file', 50),
  ('53', 'container_image', 50),
  ('54', 'prediction_file', 51),
  ('55', 'container_image', 52),
  ('56', 'container_image', 53),
  ('57', 'container_image', 54),
  ('58', 'container_image', 55),
  ('59', 'other', 56),
  ('60', 'prediction_file', 57),
  ('61', 'container_image', 58),
  ('62', 'prediction_file', 59),
  ('63', 'prediction_file', 60),
  ('64', 'prediction_file', 61),
  ('65', 'prediction_file', 62),
  ('66', 'prediction_file', 63),
  ('67', 'prediction_file', 64),
  ('68', 'prediction_file', 65),
  ('69', 'prediction_file', 66),
  ('70', 'prediction_file', 67),
  ('71', 'prediction_file', 68),
  ('72', 'prediction_file', 69),
  ('73', 'prediction_file', 70),
  ('74', 'prediction_file', 71),
  ('75', 'prediction_file', 72),
  ('76', 'prediction_file', 73),
  ('77', 'prediction_file', 74),
  ('78', 'prediction_file', 75),
  ('79', 'prediction_file', 76),
  ('80', 'prediction_file', 77),
  ('81', 'prediction_file', 78),
  ('82', 'prediction_file', 79),
  ('83', 'prediction_file', 80),
  ('84', 'prediction_file', 81),
  ('85', 'prediction_file', 82),
  ('86', 'prediction_file', 83),
  ('87', 'prediction_file', 84),
  ('88', 'prediction_file', 85),
  ('89', 'prediction_file', 86),
  ('90', 'container_image', 86),
  ('91', 'other', 87),
  ('92', 'other', 88),
  ('93', 'other', 89),
  ('94', 'prediction_file', 90),
  ('95', 'prediction_file', 91),
  ('96', 'prediction_file', 92),
  ('97', 'prediction_file', 93),
  ('98', 'prediction_file', 94),
  ('99', 'prediction_file', 95),
  ('100', 'prediction_file', 96),
  ('101', 'prediction_file', 97),
  ('102', 'prediction_file', 98),
  ('103', 'prediction_file', 99),
  ('104', 'prediction_file', 100),
  ('105', 'prediction_file', 101),
  ('106', 'prediction_file', 102),
  ('107', 'prediction_file', 103),
  ('108', 'container_image', 104),
  ('109', 'prediction_file', 105),
  ('110', 'container_image', 105),
  ('111', 'prediction_file', 106),
  ('112', 'container_image', 107),
  ('113', 'notebook', 108),
  ('114', 'notebook', 109),
  ('115', 'notebook', 110),
  ('116', 'notebook', 111),
  ('117', 'notebook', 112),
  ('118', 'notebook', 113),
  ('119', 'notebook', 114),
  ('120', 'notebook', 115),
  ('121', 'notebook', 116),
  ('122', 'notebook', 117),
  ('123', 'notebook', 118),
  ('124', 'notebook', 119),
  ('125', 'notebook', 120),
  ('126', 'notebook', 121),
  ('127', 'notebook', 122),
  ('128', 'notebook', 123),
  ('129', 'notebook', 124),
  ('130', 'notebook', 125),
  ('131', 'notebook', 126),
  ('132', 'notebook', 127),
  ('133', 'notebook', 128),
  ('134', 'notebook', 129),
  ('135', 'notebook', 130),
  ('136', 'notebook', 131),
  ('137', 'notebook', 132),
  ('138', 'notebook', 133),
  ('139', 'notebook', 134),
  ('140', 'notebook', 135),
  ('141', 'notebook', 136),
  ('142', 'notebook', 137),
  ('143', 'notebook', 138),
  ('144', 'notebook', 139),
  ('145', 'notebook', 140),
  ('146', 'notebook', 141),
  ('147', 'notebook', 142),
  ('148', 'notebook', 143),
  ('149', 'notebook', 144),
  ('150', 'notebook', 145),
  ('151', 'notebook', 146),
  ('152', 'notebook', 147),
  ('153', 'notebook', 148),
  ('154', 'notebook', 149),
  ('155', 'notebook', 150),
  ('156', 'notebook', 151),
  ('157', 'notebook', 152),
  ('158', 'notebook', 153),
  ('159', 'notebook', 154),
  ('160', 'notebook', 155),
  ('161', 'notebook', 156),
  ('162', 'prediction_file', 157),
  ('163', 'other', 158),
  ('164', 'other', 159),
  ('165', 'other', 160),
  ('166', 'prediction_file', 161),
  ('167', 'prediction_file', 162),
  ('168', 'other', 162),
  ('169', 'prediction_file', 163),
  ('170', 'other', 163),
  ('171', 'prediction_file', 164),
  ('172', 'prediction_file', 165),
  ('173', 'prediction_file', 166),
  ('174', 'other', 166);

-- challenge_star data

INSERT INTO challenge_star (id, challenge_id, user_id)
VALUES ('1', 1, 1),
  ('2', 2, 1),
  ('3', 1, 2);

-- challenge_x_challenge_input_data_type definition

INSERT INTO challenge_x_challenge_input_data_type (id, challenge_id, challenge_input_data_type_id)
VALUES ('1', 1, 1),
  ('2', 2, 1),
  ('3', 1, 2),
  ('4', 4, 4);
